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CHAPTER 1
INTRODUCTION
Recent improvement in accessibility of high-throughput DNA sequencing brought
a great deal of attention to disease association and susceptibility studies. Successful genomewide searches for disease-associated gene variations have been recently reported [140, 144].
However, complex diseases can be caused by combinations of several unlinked gene
variations. This work addresses computational challenges of genotype data analysis studies
including haplotype inference, informative SNPs se-lection, searching for diseases associated
SNPs, and predicting of genotype susceptibility.
Disease association studies analyze genetic variation across cases (diseased individuals) and
controls (healthy individuals). The difference between individual DNA sequences occurs at
single-base sites, in which more than one allele is observed across population. Such variations
are called single nucleotide polymorphisms (SNPs). The number of simultaneously typed SNPs
for association and linkage studies is reaching 106 for SNP Mapping Arrays [131]. High density
maps of SNPs as well as massive DNA data with large number of individuals and number of
SNPs become publicly available [156].
Diploid organisms, like human, have two near-identical copies of each chromosome. Most
genotyping techniques (e.g., SNP Mapping Arrays [131]) do not provide separate SNP sequences
(haplotypes) for each of the two chromosomes. Instead, they provide SNP sequences
(genotypes) representing mixtures of two haplotypes -- each site is defined by an unordered
pair of allele readings, one from each haplotype -- while haplotypes are computationally
inferred from genotypes [101].
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Given the likely complexity of trait determination, it is widely assumed that the genetic
basis (if any) of important traits (e.g., diseases) can be best understood by assessing the
association between the occurrence of particular haplotypes and particular traits. Hence, one
of the challenges addressed in this work is computational inferring of the haplotypes
(Phasing).

1.1 Haplotype Inference
The input to the phasing problem consists of n genotype vectors each with m
coordinates corresponding to SNPs.

The phasing problem asks for explaining each

genotype with two haplotypes corresponding to chromosomes. In general as well as in
common biological setting, there is exponential number of possible haplotype pairs for
the same input genotype. Indeed, an individual genotype with k heterozygous sites
can have 2k-1 haplotype pairs that can resolve this genotype.

Without additional

biological insight, one cannot deduce which of the exponential number of solutions is
the most biologically meaningful and, therefore, would serve as a good guess for the
real underlying haplotypes.
Several methods have been explored and some are intensively used for this task [6, 7, 12,
14, 20, 18, 19]. None of these methods are presently fully satisfactory, although many
give impressively accurate results.
Although the main concern of phasing algorithms is the accuracy of the inferred haplotypes,
the emerging volume of collected genotype data brought more attention to the running time of
such methods. Indeed, the leading phasing software tool PHASE [95] is getting hard time in
competing with generally less accurate but much faster tools such as HAPLOTYPER [41]
and GERBIL [87].
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In this work, we first explore phasing of genotypes with two SNPs which have
ambiguity when the both sites are heterozygous. Then there are two possible phasings (so called
cis- and trans-) and we assume that the true phasing tends to choose the most frequent pair
of haplotypes observed in the population sample.

Complete haplotypes for a given

genotype can be inferred based on the maximum spanning tree of a complete graph with
vertices corresponding to heterozygous sites and edge weights given by inferred 2-SNP
frequencies. On datasets across 23 chromosomal regions from HapMap [86], proposed
(2SNP) method is several orders of magnitude faster than GERBIL and PHASE while
matching them in quality measured by the number of correctly phased genotypes, single-site
and switching errors.
Frequently, genotype data represent family trios consisting of the two parents and their
child since that allows to recover haplotypes with higher confidence. A simple logical
analysis allows to substantially decrease uncertainty of phasing. For example, for two SNPs
in a trio with parent genotypes f = 22 and m = 02, and the child genotype k = 01, there
is a unique feasible phasing of the parents: f1 = 10, f2 = 01, m1 = 01, m2 = 00 such that the
haplotypes f2 and m1 are inherited by the child. In fact, it is not difficult to check that
logical ambiguity exists only if all three genotypes have 2's in the same SNP site.
Although, there exist many phasing methods for unrelated adults or pedigrees, phasing
and missing data recovery for trios is lagging behind. We have tried several well-known
computational methods for phasing Daly et al. [138] family trio data, but, surprisingly, all
of them give infeasible solutions with high inconsistency rate.
In this work we propose an integer linear programming and greedy methods for solving
phasing problem for family trios by finding most Parsimonious solution. We have also
enhanced our 2SNP algorithm to phase family trio data. 2SNP trio phasing have been
compared with four other well-known phasing methods on simulated data from [90]. 2SNP is
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much faster than all of them while loosing in quality only to PHASE.

1.2 Disease Association Search
Several challenges in genome-wide association studies of complex diseases have
not yet been adequately addressed [137]: interaction between non-linked genes, multiple
independent causes, multiple testing adjustment, etc.

Since complex common

diseases can be caused by multi-loci interactions two-locus analysis can be more powerful than
traditional

one-by-one

SNP

association

analysis

[143].

Multi-loci

analysis

is

expected to find even deeper disease-associated interactions. The computational challenge (as
pointed in [137]) is caused by the dimension catastrophe. Indeed, two-SNP
interaction analysis (which can be more powerful than traditional one-by-one SNP
association analysis [143]) for a genome-wide scan with 1 million SNPs (3 kb coverage) will afford 1012 possible pair wise tests.

Multi-SNP interaction analysis reveals

even deeper disease-associated interactions but is usually computationally infeasible
and its statistical significance drastically decreases after multiple testing adjustment
[121, 125].
Disease association analysis searches for Risk Factors (RF) modeled as multi-SNP
combinations (MSC) (,i.e., subsets of SNP's with specified alleles) with frequency among
diseased individuals (cases) considerably higher than among non-diseased individuals
(controls). Only statistically significant MSCs (whose frequency distribution has p-value less
than 0.05) are reported. Successful as well as unsuccessful searches for SNPs with statistically
significant association have been recently reported for different diseases and different
suspected human genome regions (see e.g. [151]). Unfortunately, reported findings are
frequently not reproducible on different populations. It is believed that this happens because
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the p-values are unadjusted to multiple testing -- indeed, if the reported SNP is found among
100 SNPs then the probability that the SNP is associated with a disease by mere chance
becomes roughly 100 times larger. This work focuses on optimization approach to resolve
these issues instead of traditionally used statistical and computational intelligence methods.
In order to handle data with huge number of SNPs, one can extract informative
(indexing) SNPs that can be used for (almost) lossless reconstructing of all other
SNPs[130]. To avoid information loss, index SNPs are chosen based on how well the other
non-index SNPs can be reconstructed. The corresponding informative SNP selection
problem (ISSP) can be formulated as follows.
Given a sample S of a population P of individuals (either haplotypes or genotypes) on m
SNPs, select positions of k (k < m) SNPs such that for any individual, one can predict
non-selected SNPs from these k selected SNPs. The Multiple Linear Regression based
MLR-tagging algorithm [112] solves the optimization version of ISSP which asks for k
informative SNPs minimizing the prediction error measured by the number of incorrectly
predicted SNPs. The number of tags (informative SNPs) k depends on the desirable data
size. More tags will keep more genotype information while less tags allows deeper analysis
and search. In the reduced set of SNPs one can search for deeper disease association.
We

next

discuss

the

optimization

problem

of

finding

the

most

disease-

associated risk factor (RF) for given case-control data. Since it is plausible that common
diseases can have also genetic resistance factors, one can also search for the most diseaseresistant risk factor. Association of risk or resistance factors with the disease can be
measured in terms of p-value of the skew in case and control frequencies, risk rates or odds
rates. Here we concentrate on three association measurements: p-value of the skew in case
and control frequencies, odds ratio (OR) of corresponding risk factor, and positive predictive
value (PPV) which is the frequency of case individuals among all individuals with a given
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multi-SNP combination.

This optimization problem is NP-hard and can be viewed as a generalization
of the maximum independent set problem. Therefore, we have applied our exhaustive,
combinatorial and complimentary greedy search heuristics [132, 133], alternating
combinatorial, and randomized complimentary greedy searches to solve this problem.
Although complimentary greedy search and randomized complimentary greedy search cannot
guarantee finding of close to optimum RFs, in the experiments with real data, they find RFs
with non-trivially high OR and PPV. For example, for Crohn's disease data [138],
complimentary greedy search finds in less than second a case-free (disease-resistant) RF
containing 24 controls, while exhaustive and combinatorial searches need more than 1 day to
find case-free RFs with at most 17 controls.
We next model atomic risk factors (ARF's) (i.e., SNP risk factors that cannot be split into
simpler factors) for common diseases as a multi-SNP combination (MSC), i.e., subsets of SNP's
with specified alleles. Our first optimization formulations ask for a MSC the most tightly
associated with the disease (i.e., minimizing p-value) [132] and having the highest positive
predictive value which is the case frequency among exposed to ARF individuals [133]. In
contrast, epidemiologists measure the quality of risk factors in case-control studies by odds
ratio defined as the ratio of the odds of disease occurring in the exposed (to the risk factor)
group to the odds of it occurring in unexposed group. Thus, we ask for an ARF with the
maximum odds ratio. We show connection of this problem with the known Red-Blue Set
Cover problem [166] and apply the complementary greedy search (CGS) algorithm [133].
We next propose to consider more complex but also more relevant SNP risk factors, so called krelaxed atomic risk factors, for which exposed individuals can deviate in at most k sites from
a given MSC. We generalize the complimentary greedy algorithm (k-CGS) to find k-relaxed
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atomic risk factors with fixed k. Our experiments show advantage of the new method over
CGS in finding risk factors with significantly higher odds ratio and association with the disease.
We then introduce even more general risk factors, so called weighted relaxed atomic
risk factors. The individuals exposed to such factors should be within weighted Hamming
distance k from a given MSC. We also proposed a novel heuristic (WCGS) for finding
weighted relaxed ARF with odds ratio.
We have applied and cross-validated CGS [133], k-CGS, and WCGS methods for finding
atomic risk factors (ARF), k-relaxed ARF's and weighted relaxed ARF's, respectively,
with large odds ratios on real case-control studies for several diseases (Crohn's disease [138],
autoimmune disorder [163], tick-born encephalitis [134], lung cancer [144], and rheumatoid
arthritis [135]). New proposed methods found SNP risk factors that are statistically significant
even after multiple-testing adjustment on all data while CGS could not find significant
ARF on two of these data. The found relaxed atomic risk factors explain much higher
number of cases, 1.5-4 times larger than atomic ARFs found by CGS.
The next challenge commonly facing disease-association studies [136] is finding
reproducible associations. This challenge have been traditionally addressed in statistics [143]
while here we apply computational approaches -- permutation tests and cross-validation.
To measure and compare the significance of found risk factors we use traditional permutation
tests. To measure and compare ability of search methods to find reproducible risk factors, we
propose to apply cross-validation scheme usually used for prediction validation.
We have applied our search methods to real case-control studies for several diseases (Crohn's
disease [138], autoimmune disorder [163], tick-born encephalitis [134], lung cancer [144], and
rheumatoid arthritis [135]). Proposed methods are compared favorably to the exhaustive
search -- they are faster, find more frequently statistically significant risk factors and have
significantly higher leave-half-out cross-validation rate.
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1.3 Disease Susceptibility Prediction
Some complex diseases, such as psychiatric disorders, are characterized by a non
mendelian, multifactorial genetic contribution with a number of susceptible genes interacting
with each other [161, 147]. In general, a single SNP or gene may be impossible to associate
because a disease may be caused by completely different modifications of alternative pathways.
Furthermore, there are no reliable tools applicable to large genome ranges that could rule out or
confirm association with a disease. It is even difficult to decide if a particular disease is genetic,
e.g., the nature of Crohn's disease has been disputed [146]. Although answers to above
questions may not explicitly help to find specific disease-associated SNPs, they may be critical
for disease prevention. Indeed, knowing that an individual is (or is not) susceptible to (or belong
to a risk group for) a certain disease will allow greatly reduce the cost of screening and
preventive measures or even help to completely avoid disease development, e.g., by changing a
diet.
This study is devoted to the problem of assessing accumulated information targeting to
predict genotype susceptibility to complex diseases with significantly high accuracy and
statistical power. We first formulate disease susceptibility prediction problem (see
[142, 158, 159, 162, 164]) and describe several universal classifiers and discrete optimization
based algorithms for prediction disease susceptibility. We then compare leave-one- and leavemany-out tests demonstrating that prediction accuracy of suggested methods is sufficiently
resilient to discarding case-control data implying that leave-one-out test is a trustworthy
accuracy measure. The permutation tests have been used for computing the statistical
significance level of proposed methods and resulted prediction weights.
The proposed methods have been favorably compared with well known universal
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classifiers ,e.g., SVM, Random Forest, etc., on two publicly available datasets of: Crohn's
disease [153] and autoimmune disorder [163]. In the leave-one-out cross-validation tests the
proposed linear programming (LP) based method achieves prediction rate of 69.5%(p-value
below 2%) and 61.3%(p-value below 62%) and the risk rates of 2.23 and 0.98, respectively.
The last problem addressed in this work is the disease susceptibility prediction
problem exploiting the developed methods for searching associated risk and
resistance factors. A novel optimum clustering problem formulation has been proposed [133].

Also a model-fitting method has been suggested which transforms a

clustering algorithm into the corresponding model-fitting susceptibility prediction algorithm.
Since common diseases can be caused by multiple independent and coexisting factors, an
association-based clustering of case/control population has been proposed [133]. The resulted
association-based combinatorial prediction algorithm significantly outperforms existing
prediction methods. For all three real data sets that were available to us (Crohn's disease
[138], autoimmune disorder [163], and tick-borne encephalitis [100]) the accuracy of the
prediction based on combinatorial search is respectively, 76%, 74%, and 80%, which is higher
by 7% compared to the accuracy of all previously proposed methods implemented in [142,
118]. The accuracy of the prediction based on complimentary greedy search almost matches
the best accuracy but is much more scalable.

1.4 Overview
Chapter 2 introduces SNPs, haplotypes, genotypes, and formally describes the phasing
of complete unrelated genotypes and family trios. Several previously know methods are
presented and motivation for designing new more accurate and faster methods is given. Here
we introduce optimization formulation for family trios phasing problem and propose integer
linear programming and greedy methods for solving it. We also describe our accurate and
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scalable combinatorial method for genotype phasing (2SNP). Each of the proposed methods is
favorably compared with existing methods.
Chapter 3 introduces case-control study and gives motivation behind diseaseassociation search (DAS). The DAS problem is formally defined and several previously
known approaches are presented. The motivation for designing new robust methods
for DAS which can be applied to diseases caused by multiple genes is given.

The

DAS problem is formulated as an optimization problem for finding the maximum
control-free cluster corresponded or maximum odds ratio atomic risk factor and the
fast greedy heuristic to solve this problem is proposed. A complex risk factor (RF) is
proposed to model as close (non-weighted or weighted) match to a MSC (e.g.,
no more than k mismatches) k-relaxed atomic risk factor or weighted relaxed atomic
risk factor and the optimization formulation asks for RF with the maximum odds
ratio. For measuring and comparing the significance of found risk factors we describe
traditional permutation tests.

Then we describe proposed cross-validation scheme

for measuring and comparing ability of search methods to find reproducible risk factors. Next
we present our extensive experimental studies which consist of searching for
disease-associated risk factor in several real case-control study data. We also present
comparison of searching methods by ability to find disease-associated risk factors and
reproducibility of these factors.
Chapter 4 introduces the problem of disease-susceptibility prediction (DSP) and motivation
behind it. Then two general approaches for DSP are described -- universal classifier
approaches and disease association-based combinatorial approaches. Next we present several
universal classifier methods and our new LP-based prediction method for DSP. Also in this
chapter we formulate optimum disease clustering problem and describe our diseaseassociation based model-fitting prediction method for DSP. We finalize this chapter with
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experimental study of existing and proposed methods on several real case-control study
datasets.
Chapter 5 describes our software packages: TrioPhasing -- the code which implements
the integer linear programming method for trio phasing; 2SNP -- the code which implements
our fast, scalable and accurate 2SNP phasing algorithm; DACS -- software which
implements several algorithms for solving DAS and DSP problems; GeneSuscept -- software
which implements the LP-based algorithm for DSP problem.
Chapter 6 describes our future work followed by related publications and bibliography.
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CHAPTER 2
POPULATION-BASED PHASING AND MISSING DATA RECOVERY

A "haplotype" is a DNA sequence that has been inherited from one parent. Each person
possesses two haplotypes for most regions of the genome. The most common type of
variation among haplotypes possessed by individuals in a population is the single nucleotide
polymorphism (SNP), in which different nucleotides (alleles) are present at a given site (locus).
Almost always, there are only two alleles at a SNP site among the individuals in a population.
Given the likely complexity of trait determination, it is widely assumed that the genetic
basis (if any) of important traits (e.g., diseases) can be best understood by assessing the
association between the occurrence of particular haplotypes and particular traits. Hence, one
of the current priorities in human genomics is the development of a full Haplotype Map of the
human genome [1, 46, 47, 17], to be used in large-scale screens of populations [16, 53]. In this
endeavor, a key problem is to infer haplotype pairs and/or haplotype frequencies from
genotype data, since collecting haplotype data is generally more difficult than collecting
genotype data. Here, we review the haplotype inference problem (inferring pairs and inferring
frequencies), the major combinatorial and statistical methods proposed to solve these two
problems, and the genetic models that underlie these methods.
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2.1

Introduction to Variation, SNPs, Genotypes, and Haplotypes
Now that high-throughput genomic technologies are available, the dream of assessing

DNA sequence variation at the population level is becoming a reality. The processes of
natural selection, mutation, recombination, gene-conversion, genome rearrangements, lateral
gene transfer, admixture of populations, and random drift have mixed and remixed alleles at
many loci so as to create the large variety of genotypes found in many populations. The
challenge is to find those genotypes that have significant and biologically meaningful
associations with important traits of interest. A key technological and computational part of
this challenge is to infer "haplotype information" from "genotype information". In this
section, we explain the basic biological and computational background for this "genotype to
haplotype" problem.
In many diploid organisms (such as humans) there are two (not completely identical) "copies"
of almost all chromosomes. Sequence data from a single copy is called a haplotype, while a
description of the conflated (mixed) data on the two copies is called a genotype. When
assessing the genetic contribution to a trait, it may often be much more informative to
have haplotype data than to have only genotype data. The underlying data that form a
haplotype are either the full DNA sequence in the region, the number of repeats at
microsatellite markers, or more commonly the single nucleotide polymorphisms (SNPs) in
that region. A SNP is a single nucleotide site where more than one (usually two) nucleotides
occur with a population frequency above some threshold (often around 5-10%). The SNPbased approach is the dominant one, and high-density SNP maps have been constructed
across the human genome with a density of about one SNP per thousand nucleotides [47, 17].

2.1.1

The Biological Problem

In general, it is not easy to examine the two copies of a chromosome separately, and
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genotype data rather than haplotype data are obtained, although it is the haplotype data that may
be of greater use. The data set typically consists of n genotype vectors, each of length m, where
each value in the vector is either 0, 1, or 2. The variable n denotes the number of individuals in
the sample, and m denotes the number of SNP sites for which one has data. Each site in the
genotype vector has a value of 0 (respectively 1) if the associated site on the chromosome has
state 0 (respectively 1) on both copies (it is a homozygous site); it has a value of 2 otherwise (the
chromosome site is heterozygous). The goal is to extract haplotype information from the
given genotype information.
A variety of methods have been developed and used to do this (e.g., [14, 15, 28, 36, 42,
58, 61, 63, 66, 69]). Some of these methods give very accurate results in some
circumstances, particularly when identifying common haplotypes in a population. However,
research on haplotype inference continues because no single method is considered fully
adequate in all applications, the task of identifying rare haplotypes remains difficult, and the
overall accuracy of present methods has not been resolved.

2.1.2

The Computational Problems

The haplotype inference (HI) problem can be abstractly posed as follows. Given a set of n
genotype vectors, a solution to the HI problem is a set of n pairs of binary vectors, one pair for
each genotype vector. For any genotype vector g, the associated binary vectors v1; v2 must both
have value 0 (or 1) at any position where g has value 0 (or 1); but for any position where g
has value 2, exactly one of v1; v2 must have value 0, while the other has value 1.
A site in g is considered "resolved" if it contains 0 or 1, and "ambiguous" if it contains
a 2. If a vector g has zero ambiguous positions, it is called "resolved" or "unambiguous";
otherwise it is called "ambiguous". One can also say that the conflation of v1 and v2
produces the genotype vector g, which will be ambiguous unless v1 and v2 are identical.
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For an individual with h heterozygous sites there are 2h-1 possible haplotype pairs that could
underlie its genotype. For example, if the observed genotype g is 0212, then one possible
pair of vectors is 0110, 0011, while the other is 0111, 0010. Of course, we want to infer the
pair that gave rise to the genotype of each of the n individuals.

A related problem is to estimate the frequency of the haplotypes in the sample. We call
this the HF problem. It is important to note that a solution to the HI problem necessarily
solves the HF problem, but the converse is not true.

2.1.3

The Need for a Genetic Model

Non-experimental haplotype inference (the HI and HF problems) would likely be
inaccurate without the use of some genetic model of haplotype evolution to guide an
algorithm in constructing a solution. The choice of the underlying genetic model can
influence the type of algorithm used to solve the associated inference problem.

2.1.4

Family Trio Phasing

Frequently, genotype data represent family trios consisting of the two parents and their
child since that allows to recover haplotypes with higher confidence. A simple logical
analysis allows to substantially decrease uncertainty of phasing. For example, for two SNPs
in a trio with parent genotypes f = 22 and m = 02, and the child genotype k = 01, there
is a unique feasible phasing of the parents: f1 = 10, f2 = 01, m1 = 01, m2 = 00 such that the
haplotypes f2 and m1 are inherited by the child. In fact, it is not difficult to check that
logical ambiguity exists only if all three genotypes have 2's in the same SNP site.
Although there exist many phasing methods for unrelated adults or pedigrees, phasing
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and missing data recovery for trios is lagging behind. We have tried several well known
computational methods for phasing Daly et al. [138] family trio data, but, surprisingly, all of
them give infeasible solutions with high inconsistency rate.
In this section we deal with problems of phasing and missing data recovery on family
trios data. Formally, given a set of genotypes partitioned into family trios, the Trio Phasing
Problem (TPP) requires to find for each trio a quartet of parent haplotypes which agree
with all three genotypes. Trio Missing Data Recovery Problem (TMDRP) asks for the SNP
values missed in given genotype data.

2.2

Previous Work
There are two major approaches to solving the inference problem: combinatorial methods

and statistical methods. Combinatorial methods often state an explicit objective function
that one tries to optimize in order to obtain a solution to the inference problem.
Statistical methods are usually based on an explicit model of haplotype evolution; the
inference problem is then cast as a maximum-likelihood or a Bayesian inference problem. In the
section 2.2.1 we discuss combinatorial approaches, and statistical approaches are discussed in
section 2.2.2.

2.2.1
2.2.1.1

Combinatorial approaches
Maximum Parsimony

The earliest algorithm for haplotype reconstruction (from genotype data) was
described by Clark [1990], based on the principle of maximum parsimony. This algorithm
resolves the haplotypes following three steps:
1) identifying all unambiguous haplotypes (all homozygotes and single-site
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heterozygotes) and considering them as "resolved;"
2) determining whether each of the resolved haplotypes could be one of the alleles in the
remaining yet-to-be-phased genotypes;
3) each time a new haplotype is identified as one of the resolved ones, this new
haplotype is assumed to be known, and the remaining haplotype is added to
the resolved haplotype set.
The rationale for this algorithm is that homozygous haplotypes are probably common, and
that a phase-ambiguous genotype is likely to contain known common haplotypes. Clark [1990]
stated that when all haplotypes are resolved based on maximum parsimony, the solution is
unique and correct, and the results of Clarks algorithm based on certain empirical data are
shown to be reliable by comparison with haplotypes obtained by direct molecular methods
[Clark et al., 1998; Rieder et al., 1999].
Gusfield [2001] reformulated Clarks statement into a "maximum resolution" (MR)
problem: given a set of vectors (some ambiguous and some resolved), what is the
maximum number of ambiguous vectors that can be resolved by successive application of Clarks
inference rule? Gusfield [2001] proved that the MR problem is NP-hard and Max-SNPcomplete, which can be reduced to an integer linear programming problem. The advantages
of Clarks algorithm are that it is a relatively straightforward procedure, and it can handle a
large number of loci when haplotype diversity is rather limited in the population. The
disadvantages of Clarks algorithm are that:
1) the algorithm does not start when there are no homozygotes or single-site
heterozygotes in the population;
2) the algorithm does not give unique solutions, because the phasing results are
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dependent on the order of genotypes that need to be phased (therefore, when
there is a large number of distinct haplotypes compared to the sample size due
to the presence of recombination hotspots, Clarks algorithm sometimes cannot
resolve a relatively large fraction of heterozygous individuals);
3) although Clarks algorithm does not explicitly assume Hardy-Weinberg equilibrium
(HWE), its performance is still relatively sensitive to the extent of

deviation

from HWE [Niu et al., 2002].

2.2.1.2

Perfect and Near-Perfect Phylogeny

A phylogeny-based algorithm intends to deterministically deduce haplotype phases based on
phylogenetic reconstruction [Gusfield, 2002]. The coalescent model of haplotype evolution
tells us that without recombination, the evolutionary history for w distinct haplotypes can
be displayed as a "Perfect PHylogeny" (PPH) with w leaves, and each of the SNP sites labels
exactly one edge of the tree. Rooted in the coalescent model, there are two key assumptions of
PPH: 1) no recombination; and 2) the infinite-sites model. Under these two assumptions, a
PPH problem is stated as:
PPH: Given a set S of n genotype vectors, we would like to find a PPH T (S ), and a pairing
of the 2n leaves of T (S ) that explains S .
A PPH problem can be reduced to a classical problem of recognizing graphic matroids
[Tutte, 1960]. Although the general PPH problem is NP-hard [Steel, 1992] and multiple
solutions can be possible [Gusfield, 2002], for binary phylogenies, PPH is shown to be
linear-time solvable [Bixby and Wagner, 1988]. A program named "Perfect Phylogeny
Haplotyper" [Chung and Gusfield, 2003] was developed. More recently, Halperin and
Eskin [2004] developed an "near-perfect" phylogeny method that extends the framework of
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PPH by allowing for both recurrent mutations and recombinations. In their approach, the
multiple linked SNPs are partitioned into blocks, and for each block, they predict each
individual's haplotype. Then the block-based haplotypes are assembled together to form the
long-range haplotype utilizing the PL idea of Niu et al. [2002]. The imperfect phylogeny
method appears to be more robust than PPH, and allows the handling of missing data and
resolution of a large number of SNPs.

Overall, PPH appears to be an interesting

application of the graphical model in haplotype inference, although their accuracies remain
to be benchmarked by using extensive simulations and real datasets.

2.2.2 Statistical approaches
2.2.2.1

Expectation-Maximization (EM)

The expectation-maximization (EM) algorithm [Dempster et al., 1977] estimates
population haplotype probabilities based on maximum likelihood, finding the values of the
haplotype probabilities which optimize the probability of the observed data, based on the
assumption of HWE. Excoffier and Slatkin [1995] were the first to discuss the use of
the EM algorithm in this context. The likelihood function in the EM algorithm can be
written as
n

L ( Θ ) = P (G | Θ ) = ∏

∑ θ aθ b

(2.1)

i =1 ( a ,b ):a ⊗b = g i

where G denotes the observed unphased genotype data for n individuals, gi denotes the
observed unphased genotype data for the i-th individual, Θ denotes the overall haplotype
frequency, θa and θb denote the respective haplotype frequencies for haplotypes a and b,
such that a ⊗ b = gi denotes that the haplotype pair (a, b) is compatible with the i-th
observed genotype data-gi. The EM algorithm, under the assumption of HWE, is an
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iterative procedure: θ a( k +1) = E Θ ( k ) (na | G ) / 2n , where Θ(k) is the current estimate of
haplotype frequencies, and na is the count of haplotype a that exists in G. It can be
important that the initial values of haplotype frequencies are reasonably close to the true
population frequencies. The advantages of the EM algorithm are that: 1) it is based on solid
statistical theory; and 2) although the EM algorithm makes an explicit assumption of HWE,
simulation studies demonstrate that its performance is not strongly affected by the
departures from HWE, particularly when the direction of departure is towards an excess of
homozygosity [Niu et al., 2002]. The disadvantages are that: 1) the performance is sensitive
to the initial value of Θ; 2) if there exist local maxima, the iteration may lead to locally
optimal maximum likelihood estimates (MLEs), which becomes most serious when there are
many distinct haplotypes (one sensible way to employ the EM algorithm is to use a good
initial guess on Θ [e.g., the product of the allele frequencies, as suggested by Excoffier
and Slatkin, 1995]); and 3) the standard EM algorithm cannot handle a large number of
loci.

Recently, a variant on the EM algorithm, the stochastic-EM algorithm,

was applied to the problem of estimation haplotypes from unphased genotypes, by
Tregouet et al. [2004]. This algorithm can be useful for avoiding convergence to local
maxima.

2.2.2.2

Coalescent-Based Algorithm

Stephens et al. [2001] proposed a coalescence based Markov-chain Monte Carlo (MCMC)
approach: a pseudo-Gibbs sampler (PGS) for reconstructing haplotypes from genotype
data. PGS uses Gibbs sampling to obtain an approximate sample from the posterior
distribution, P (Z|G), where Z = (z1, z2,…, zn) and G = (g1, g2,…, gn) denote the phased and
unphased (i.e., observed) genotype data for n individuals. The major piece of this iterative
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sampling algorithm is that at the (k + 1)-th iteration, we aim to sample z i( k +1) from

P ( z i | G, Z −ki ) , where Z −ki is a set of phased genotypes for all the remaining (n - 1)
subjects excluding the haplotype pair zi for individual i, at the k-th iteration. Then, we
have P( Z i | G, Z −ki ) ∝ P( z i = α ⊗ β | Z −ki ) ∝ π (α | Z −i )π ( β | Z −i , α ) , where α and β

denote the two respective haplotypes that form zi : Here, π (α | Z −i ) is essentially a prior
for a future sampled haplotype, which is not known to the investigators a priori. Instead of
using the Dirichlet prior [based on the "parent-independent mutation" model in Stephens et
al., 2001], Stephens et al. [2001] suggested using an approximate coalescent prior: equation
17 of Stephens and Donnelly [2000], which is a stationary Markov chain with
transition matrix

Tah =

θ
r +θ

Pah +

rα
r +θ

, where r and rα are the total number of haplotypes and the total number of type α
haplotypes in Z, respectively, θ is the scale mutation rate, and P is the transition matrix.
The approximate coalescent prior is based on the assumption that "the genetic sequence of
a mutant offspring will differ only slightly from the progenitor sequence (often by a singlebase change)" [Stephens and Donnelly, 2003]. Recently, Stephens and Donnelly [2003]
modified the implementation of the PGS algorithm by incorporating a variant of the
partitionligation (PL) idea [Niu et al., 2002] and by allowing for recombination and decay
of linkage disequilibrium (LD) with distance. The key advantage of the PGS is that it
incorporates the coalescence theory into its prior, and although the induced Markov chain
has a stationary distribution that may depend on the order of gis, it was shown to perform
well in simulations based on a coalescent model: a constant-size population evolving for a
long period of time without recombination or recurrent mutations [Stephens et al., 2001;
Stephens and Donnelly, 2003]. The disadvantages are that:
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1.

PGS is not a fully Bayesian model and it lacks a measure of the overall "good ness"
of the constructed haplotypes;

2.

because this algorithm makes only local moves in each iteration (i.e., a "piece-bypiece" strategy) to update a new haplotype that closely resembles an existing
haplotype, PGS is quite slow and it takes millions of iterations for the algorithm (2
million iterations are suggested as the default value for PHASE version 1.0 in
Stephens and Donnelly [2003]) to start to converge to the right answer [e.g., the
ACE data from Rieder et al., 1999];

3.

it remains unclear whether the algorithm performs favorably compared to other
algorithms (e.g., standard EM algorithm) for admixed or rapidly expanding
populations when the coalescent model does not hold, which is often the case for
cosmopolitan US cohorts (e.g., a random sample from downtown Los Angeles).

For example, although Stephens et al. [2001] demonstrated that PHASE outperformed
EM by a significant margin under certain conditions, Zhang et al. [2001] and Xu et al. [2002]
revealed that this was not the case: PHASE and EM-based methods exhibited similar
performances in their simulated datasets.

2.2.3 Family Trio Phasing Approaches

In this section we overview previous research and on phasing based on statistical methods
(Phamily and PHASE, HAPLOTYPER, HAP and greedy algorithms). The ILP based
approaches will be discussed in the next section.
Stephens et al. [95] introduced a Bayesian statistical method PHASE for phasing genotype
data. It exploits ideas from population genetics and coalescent theory that make phased
haplotypes to be expected in natural populations. It also estimates the uncertainty associated
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with each phasing. The software can deal with SNP in any combination, any size of
population and missing data are allowed. The drawback of this method is that it takes long
time for large population
Acherman et al. [27] described the tool Phamily for phasing the trio families based on wellknown phasing tool PHASE [95]. It first uses the logical method described above to infer
the SNPs in the parental haplotypes. Then children genotypes are discarded while the
parental genotypes and known haplotypes are passed to PHASE. Because the children genotypes
are discarded, PHASE no longer can maintain parent-child trio constraints resulting in 8.02%
error rate for phasing Daly et al [138] data.
Niu et al [41] proposed a new Monte Carlo approach HAPLOTYPER for phasing genotype
data. It first partition the whole haplotype into smaller segments then use the Gibbs sampler
both to construct the partial haplotypes of each segment and to assemble all the segments
together. This method can accurately and rapidly infer haplotypes for a large number of
linked SNPs. The drawback of HAPLOTYPER is that it can not handle lengthy genotype
with large population. It limits 100 SNPs and 500 population.
Halperin et al. [35] used the greedy method for phasing and missing data recovery. For
each trio the author introduce four partially resolved haplotypes with the
coordinates 0, 1 and ?.

The values of 0 and 1 correspond to fully resolved SNPs

which can be found via logical resolution from the section 2.4.1, while the ?'s corresponds
to ambiguous and missing positions. The greedy algorithm iteratively finds the complete
haplotype which covers the maximum possible number of partial haplotypes, removes this set
of resolved partial haplotypes and continues in that manner. The authors replace each
genotype in Daly et al [138] data with a pair of logically partial resolved haplotypes
referring to each ambiguous SNP value as a ?. The ?'s constitute 16% of all data. Then extra
10% of data are erased (i.e., replaced with ?'s) and the resulted 26% of ambiguous SNP values
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are inferred by the greedy algorithm minimizing haplotype variability within blocks. When
measured on the additionally erased 10% of data, the error rate for the greedy algorithm is
2.8% [35] which has been independently confirmed in our computational experiments.
Unfortunately, the error rate o for the original 16% of ?'s is at least 25% which has been
measured by the number of inconsistently phased SNPs. This may lead to a conclusion that
the complexity of missing genotype data is considerably higher than the complexity of the
successfully genotyped data.

2.3

2SNP: Scalable Phasing Method for Unrelated Individuals

Emerging microarray technologies allow affordable typing of very long genome sequences.
A key challenge in analyzing of such huge amount of data is scalable and accurate
computational inferring of haplotypes (i.e., splitting of each genotype into a pair of
corresponding haplotypes). In this work, we propose a phasing method which first phase
genotypes consisting only of two SNPs using genotypes frequencies adjusted to the random
mating model and then extend phasing of two-SNP genotypes to phasing of complete
genotypes using maximum spanning trees. Runtime of the proposed 2SNP algorithm is
O(nm(n + log m), where n and m are the numbers of genotypes and SNPs, respectively,

and it can handle genotypes spanning entire chromosomes in a matter of hours.
On datasets across 23 chromosomal regions from HapMap [86], 2SNP is several orders of
magnitude

faster

than

GERBIL(combinatorial

method)

and

PHASE(statistical

method) while matching them in quality measured by the number of correctly phased
genotypes, single-site and switching errors. For example, 2SNP requires 4 s on Pentium 4 3Ghz
processor

to

phase

30

genotypes

with

1500

SNPs

(ENm010.7p15:2

data

from HapMap) versus GERBIL and PHASE requiring more than a week of runtime
and admitting no less errors than 2SNP. For genotypes with more than 1500 SNPs
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PHASE and GERBIL fall into infinite loop. However, 2SNP software phases entire
chromosome (105 SNPs from HapMap) for 30 individuals in 2 hours with average
switching error 7.7%.

2.3.1 Introduction

The difference between individual DNA sequences mostly occurs at single-base sites, in
which more than one nucleic acid or gap is observed across the population. Such variations
are called single nucleotide polymorphisms (SNPs). The number of sufficiently frequent
SNPs in the human population is estimated to be around 10 million [88]. For complex
diseases caused by more than a single gene, it is important to identify a set of alleles inherited
together. Identification of haplotypes, the sequences of alleles in contiguous SNP sites along a
chromosomal region, is a central challenge of the International HapMap project [86]. The
number of simultaneously typed SNPs for association and linkage studies is reaching 500,000
for SNP Mapping Arrays from Affymetrix [131].
Diploid organisms, like human, have two near-identical copies of each chromosome. Most
experimental techniques for determining SNPs do not provide the haplotype information
separately for each of the two chromosomes. Instead, they generate for each site an unordered
pair of allele readings, one from each copy of the chromosome, which is called a genotype.
The input to the phasing problem consists of n genotype vectors each with m
coordinates corresponding to SNPs. The phasing problem asks for explaining each genotype
with two haplotypes corresponding to chromosomes. In general as well as in common
biological setting, there are 2k-1 possible haplotype pairs for the same input genotype with k
heterozygous sites.
Computational inferring of haplotypes from the genotypes (or phasing) has been initiated
by Clark[79] who proposed a parsimony-based approach. It has been shown later that the
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likelihood based expectation-maximization (EM) is more accurate [92]. Markov chain
Bayesian haplotype reconstruction methods have been used in PHASE [95], PLEM [91], and
HAP2 [89]. A combinatorial model based on the perfect phylogeny tree assumption was
suggested in [82]. HAP [83] exploits perfect phylogeny model and block structure showing
good performance on real genotypes with low error rates. Recently, GERBIL [87] has
combined block identification and phasing steps for reliable phasing of long genotypes.
In this work, we first explore phasing of genotypes with two SNPs which have ambiguity
when the both sites are heterozygous. Then there are two possible phasings (so called cis- and
trans-) and we assume that the true phasing tends to choose the most frequent pair of
haplotypes observed in the population sample. Complete haplotypes for a given genotype
can be inferred based on the maximum spanning tree of a complete graph with vertices
corresponding to heterozygous sites and edge weights given by inferred 2-SNP frequencies.
On datasets across 23 chromosomal regions from HapMap[86], 2SNP is several orders of
magnitude faster than GERBIL and PHASE while matching them in quality measured by
the number of correctly phased genotypes, single-site and switching errors. For example the
2SNP software phases entire chromosome (105 SNPs from HapMap) for 30 individuals in 2
hours with average switching error 7.7%. A brief description of 2SNP software can be found
in the application note [77].
The rest of the section is organized as follows. The next subsection describes phasing
of genotypes with only two SNPs. Subsection 2.3.3 describes the phasing of complete
unrelated genotypes. Subsection 2.4.6 compares the proposed phasing 2SNP algorithm with
PHASE, GERBIL, and PLEM for unrelated individuals.
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2.3.2 Phasing of 2-SNP genotypes

In this section we first formally introduce the phasing problem and suggest a LD-based
formula for the expected frequencies of cis- or trans-phasing of 2-SNP genotypes. We
conclude with adjusting of expected haplotype frequencies to deviation from the random
mating model.

The input to the phasing problem consists of n genotype vectors each with m
coordinates corresponding to SNPs. SNP values belong to {0, 1, 2, ?}, where 0's and
1's denote homozygous sites with major allele and minor allele, respectively; 2's stand
for heterozygous sites, and ?'s denote missed SNP values. Phasing replaces each genotype vector
by

two

haplotype

vectors

with

SNP

values

belonging

to

{0,

1}.

Feasible

phasing requires each 0 (resp. 1 or 2) in a genotype to be replaced with two 0's (resp.
two 1's or 0 and 1) in the haplotypes. A 2-SNP genotype 22 can be cis-phased, i.e.,
represented as 00 and 11 haplotypes, or trans-phased, i.e. represented as 01 and 10
haplotypes.
Tendency of cis- or trans- phasing. The random mating model (i.e., assumption that any

two haplotypes are equally likely to match in a genotype) implies that two homozygous
SNPs i and j tend to phase cis- or trans- according to odds ratio

λ=

F00 × F11
F01 × F10

(2.2)

where F00, F01, F10, F11 are unknown true frequencies of haplotypes with the first and the
second binary index denoting alleles of the i-th and j-th SNP, respectively. In other words,
the larger odds ratio corresponds to more frequent cis-phasing. On the other hand, we have
noticed that the additive odds ratio
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λ' =

F00 + F11
F01 + F10

describes true cis- or trans- phasing more accurately than the odds ratio (2.2) on real datasets.
It is known that many SNPs are in linkage disequilibrium (LD) and the higher LD
corresponds to the higher tendency towards cis- or trans-phasing. We can estimate how far
LD pushes additive odds ratio λ ' away from E (λ ' ) , which is expected in absence of LD,

E (λ ' ) =

F0× × F×0 + F1× × F×1
F0× × F×1 + F1× × F×0

where × in the indices denote “do not care", e.g., F0× = F01 + F00. Thus we can measure
the effect of LD between SNPs i and j by the ratio of the additive odds ratio λ ' over the
expected value of E (λ ' ) ,

LDij = λ ' / E (λ ' )

Finally, it has been observed [91, 92, 87] the higher LD between pairs of closer SNPs.
In order to discard falsely encountered LD between non-linked SNPs which are far apart,
we divide logarithm of LD by the square of the distance between the SNPs. The complete
formula for the tendency tij of cis- or trans-phasing of two homozygous SNPs i and j

expressed in observed haplotype frequencies is as follows

tij =

log LDij
(i − j ) 2

⎛ n + ( F00 F11 − F01 F10 ) /( F01 + F10 ) ⎞
⎟⎟
log⎜⎜
⎝ n − ( F00 F11 − F01 F10 ) /( F00 + F11 ) ⎠
=
(i − j ) 2

(2.3)
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where n is number of input genotypes, and F00, F01, F10, F11 are frequencies of haplotypes with
the first and the second binary index denoting alleles of the i-th and j-th SNP, respectively.
Haplotype frequencies are computed based on all genotype frequencies except 22. For 22
genotypes, the haplotype frequencies are chosen to fit best Hardy-Weinberg equilibrium
adjusted to observed deviation in single-site genotype distribution.
Adjusting observed frequencies to the random mating model. The formula for

tendency (2.3) is based on unknown true haplotype frequencies Fij's. One can calculate
only observed haplotype frequencies F*ij 's which can be extracted from all 2-SNP
genotypes except heterozygous in the both SNPs.
The distribution of cis- and trans-phasing of 22-genotypes (i.e., 2-SNP genotypes
heterozygous in the both sites) can be adjusted to the random mating model as follows.
Let C22 and P22 denote unknown numbers of trans- and cis-phasings, then C22 + P22 = G22,
where G22 is the number of 22-genotypes. Then the adjusted odds ratio λ ' can be expressed
as

F00* + F11* + P22
λ'= *
F01 + F10* + C22
where F*ij denote observed haplotype frequencies. The best-fit values of C22 and P22
should minimize the sum of differences between expected and observed genotype frequencies. It
is easy to compute the expected genotype frequencies for the random mating model, which
unfortunately can significantly deviate from the real mating.
According to the random mating model, the best values of C22 and P22 minimize the sum
of differences between expected and observed genotype frequencies. Unfortunately, the true
mating frequently has statistically significant deviation from random mating. Based on
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observed real data set we have found that genotypes heterozygous in one or both positions
should be assumed to be under-represented -- empirically they are assumed 3 times less
frequent than it follows from the random mating model.

2.3.3

Phasing of Complete Genotypes

In this section we first describe phasing of complete genotypes using tendency of cis- or
trans- phasing of pairs of 2's followed by resolving of missing data. We then show how to
modify 2SNP algorithm to phase family trios and conclude with analysis of the runtime.
Genotype Graph. For each genotype g, 2SNP constructs a genotype graph, which is a

weighted complete graph with vertices corresponding to 2's (i.e., heterozygous sites) of g.
The edge weight represents the tendency of the corresponding 2's being cis- or trans-phased
according to formula (2.3).
The maximum spanning tree of the genotype graph uniquely determines the phasing of the
corresponding genotype since it gives cis-/trans- phasing for any two 2's. Obviously, if for
any pair of 2's we know if they are cis- or trans-phased, then the entire phasing is known.
Note that [87] have applied the same construction for preliminary estimation of haplotype
frequencies rather than phasing per se. Therefore, for the edge weight, they have chosen LDbased formula over probabilities of full (i - j)-haplotypes given by maximum-likelihood
solution. Instead, edge weights in 2SNP do not account for SNPs between i and j.
Our computational experience with multiple data sets shows that the edges connecting a
pair of 2's that have at least c = 20 2's between them in the genotype g never have large
enough weight to be included in the maximum spanning tree. This may be result of fast
decreasing of LD and tendency with the distance between 2's. Therefore, the edges between
2's that are c 2's apart are safely disregarded while drastically improving runtime for
computing of G.
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Figure 2.1 2SNP Phasing Algorithm

Missing data recovery. Missing data (?'s) are inferred after phasing of 2's. Each

haplotype is partitioned into segments of length 40. For each segment h we find the closest
(with respect to Hamming distance) segment h’ and infer ?'s in h using the corresponding
values from h’.

2.3.4

Runtime

The runtime of Step 3 (see Figure 2.1) is O(n); therefore, the total runtime of Step 2 is
O(cnm), since Step 3 is repeated at most cm times. The runtime of Step 8 is O(cm log m)
since the graph G(gk) has maximum degree c. Therefore, the total runtime of Step 1 is O(cn2m
+cnm log m). Missing data recovery (Step 10) computes all pairwise Hamming distances
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between 2n haplotypes each with m SNPs requiring O(n2m) time. As a result, the total
runtime of the algorithm is O(cnm(n + log m)), where n and m are the number of genotypes
and SNPs, respectively. Figure 2.2 shows average runtime of 2SNP on datasets from HapMap.

Figure 2.2 Average runtime of 2SNP algorithm on datasets from HapMap build 35, July
2006 over all chromosomes and 3 races (European, African, and Japanese).

2.3.5

Experimental Results

In this section we first describe the datasets and quality measures. Then, we compare
our 2SNP method with PHASE-2.1.1[96], PLEM[91] and GERBIL[87] on unrelated data.
Real data sets. The comparison of phasing methods was performed on 46 real datasets

from 79 different genomic regions and on 4 simulated datasets. All real datasets represent
family trios -- the computationally inferred offspring haplotypes for offspring have been
compared with haplotypes inferred from parental genotypes.
- Chromosome 5q31: 129 genotypes with 103 SNPs derived from the 616 KB region of human
Chromosome 5q31 [138].
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- Yoruba population (D): 30 genotypes with SNPs from 51 various genomic regions, with
number of SNPs per region ranging from 13 to 114 [81].
- HapMap datasets I: 30 genotypes of Utah residents and Yoruba residents available
on HapMap by December 2005. The number of SNPs varies from 52 to 1381 across 40
regions including ENm010, ENm013, ENr112, ENr113 and ENr123 spanning 500 KB
regions of chromosome bands 7p15:2, 7q21:13, 2p16:3, 4q26 and 12q12 respectively,
and two regions spanning the gene STEAP and TRPM8 plus 10 KB upstream and
downstream.
- HapMap datasets II: entire 23 chromosomes of 30 individuals of Utah residents, Yoruba
residents, and Japanese residents available on HapMap by July 2006, build 35.

Simulated data sets.

- Random matching 5q31: 128 genotypes each with 89 SNPs from 5q31 cytokine gene
cluster generated by random matching from 64 haplotypes of 32 West African reported by
[85].
- MS-simulated data: 258 populations have been generated by MS[84] haplotype generator
(using recombination rates 0,4 and 16). From each population of 100 haplotypes with 103
SNPs we have randomly chosen one haplotype and generated 129 genotypes by random
matching.
Cis-/trans- odds ratio on real and simulated datasets. Here we point out to an

important difference between real data and data simulated using coalescent model. The odds ratio
(2.2) is one of the measures of LD between two SNPs. The odds ratio much larger than 1 or
much smaller than 1 indicates high LD. When computed for all pairs of SNPs i and j, the
averaged odds ratio
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∑
λ =
∑

i≠ j

F00 × F11

i≠ j

F01 × F10

(2.4)

averaged over real data is 1.9 while for all simulated data is very close to 1. This can be
partially explained by the fact that each SNP can be flipped over, i.e., 0 and 1 notations
for major and minor alleles. Each such flipping swaps the products F00F11 and F01F10 and
may increase λ (2.4). Therefore, we greedily flip SNPs increasing λ . For real data sets the
averaged greedily increased λ equals 2.5 while for MS-simulated data λ heavily depends on
the recombination rate. The haplotype sets generated with recombination rate r between 40
and 100 are the closest to the real datasets with respect to λ . On the other hand, the average

λ for ST 1, ST 2, and ST 3 are 1.95, 1.37, and 1.65 showing a significant deviation from the
real datasets.
Error measures. A single-site error [96] is the percent of erroneous SNPs among all SNPs

in phased haplotypes. An individual error [91] is the percent of genotypes phased with at least
one error among all genotypes. A switching error [87] is the percent of switches (among
all possible switches) between inferred haplotypes necessary to obtain a true haplotype. For
each dataset we bootstraped phasing result 100 times, and for each bootstrap sample we
computed an error. The 95% confidence interval for the error mean was computed based on
the 100 error values.
Comparison of phasing methods. Table 2.1 shows performance of four phasing

methods on real and simulated datasets. Average runtimes for HapMap datasets I are
separately reported for three ranges of genotype length in SNPs. All runs were performed on
computer with Intel Pentium 4, 3.0Ghz processor and 2 Gigabytes of Random Access
Memory. PLEM was run with 20 rounds and the 2.1.1 version of PHASE was run with the
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default parameters. The *-marked switching error is 2.9% for the earlier version PHASE2.0.2. The dashes in PLEM columns correspond to the cases when it does not output valid
phasing.

The 95% confidence intervals for the error means are computed using

bootstrapping.
From Table 2.1, one can see that 2SNP is several orders of magnitude faster
than two other phasing methods handling large datasets in a matter of seconds. The
reported mean errors with the respective 95% confidence intervals show that GERBIL,
PHASE, and 2SNP have the same accuracy for real data (Chromosome 5q31, Yoruba(D),
HapMap datasets). On the other hand, 2SNP and GERBIL are considerably outperformed
by PHASE and PLEM on some simulated data. Poor performance of 2SNP can be caused
by wrong recombination rate distribution on simulated data. For the mixed populations one
can see deterioration of all phasing methods.

2.4 Phasing and Missing data recovery in Family Trios

Although there exist many phasing methods for unrelated adults or pedigrees,
phasing and missing data recovery for data representing family trios is lagging behind.
This work is an attempt to fill this gap by considering the following problem. Given
a set of genotypes partitioned into family trios, find for each trio a quartet of parent
haplotypes which agree with all three genotypes and recover the SNP values missed in
given genotype data. Our contributions include (i) formulating the pure-parsimony
trio phasing and the trio missing data recovery problems, (ii) proposing two new
greedy and integer linear programming based solution methods, and (iii) extensive
experimental validation of proposed methods showing advantage over the previously
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known methods.

Table 2.1 Mean single-site, individual, and switching errors with 95% confidence intervals
and runtimes of PHASE, GERBIL, PLEM, and 2SNP on real and simulated datasets.

2.4.1 Pure-Parsimony Trio Phasing

Note that it is easy to find a feasible solution to TPP but the number of feasible solutions is
exponential and it is necessary to choose criteria for comparing such solutions. In [39] for
haplotyping pedigree data, the objective is to minimize recombinations. That objective is
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not suitable for TPP since the trios are not full-fledged pedigree data and contain no clues to
evidence recombination reconstruction. Thus, following [29, 82], we have decided to pursue
parsimonious objective, i.e., minimization of the total number of haplotypes.
The drawback of pure parsimony is that when the number of SNPs becomes large
(as well as the number of recombinations), then the quality of pure parsimony phasing
is diminishing [82]. Therefore, following the approach in [33], we suggest to partition
the genotypes into blocks, i.e., substrings of bounded length, and find solution for the
pure parsimony problem for each block separately. Note that in case of family trios
we have great advantage over the method of [33] since we do not need to solve the
problem of joining blocks. Indeed, for each family trio we can make four haplotype
templates (partially resolved by logic means of haplotypes) that imply unique way
of gluing together blocks to arrange complete haplotypes for the entire sequence of
SNPs.

Formally, let genotype be a vector with m coordinates each corresponding to an SNP and
having one of the following values: 0 (homozygote with major allele), 1 (homozygote with
minor allele), 2 (heterozygote), or ? (missing SNP value). Let haplotype be a vector with m
coordinates where each coordinate is either 0 or 1. We say that two haplotypes explain a
genotype if

•

for any 0 (resp. 1) in the genotype vector, the corresponding coordinates in the both
haplotype vectors are 0's (resp. 1's),

•

for any 2 in the genotype vector, the corresponding coordinates in the two haplotype
vectors are 0 and 1,

•

for any ? in the genotype vector, the corresponding coordinates in the haplotypes are
unconstrained (can be arbitrary).
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We say that four haplotypes h1, h2, h3, h4 explain a family trio of genotypes (f, m, k), if h1
and h2 explain the genotype f , h3 and h4 explain the genotype m, and h1 and h3 explain the
genotype k.
Pure-Parsimony Trio Phasing (PPTP). Given 3n genotypes corresponding to n family

trios find minimum number of distinct haplotypes explaining all trios.

2.4.2

Greedy Method for Trio Phasing

We apply the greedy algorithm from Halperin [35] for trio phasing. For each trio we
introduce four partial haplotypes with the coordinates 0, 1 and ?. The values of 0 and 1
correspond to fully resolved SNPs which can be found via logical resolution from the section
4.1, while the ?'s corresponds to ambiguous and missing positions. The greedy algorithm
iteratively finds the complete haplotype which covers the maximum possible number of partial
haplotypes, removes this set of resolved partial haplotypes and continues in that manner. The
drawback of this greed method is to introduce error to trio constraint, even for phasing with
error O(m) to the maximum concentration. In the future, we will try to modify the greedy
algorithm to overcome its shortcoming.

2.4.3

Integer Linear Program for Trio Phasing

We have implemented the following integer linear program (ILP) formulation (2.5)(2.8) for pure-parsimony trio phasing. It uses 0-1 variable xi for each possible haplotype
with the minimization objective:
Minimize Σ xi

(2.5)
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For each trio we introduce four template haplotypes, i.e., haplotypes with the coordinates
0,1,2 and ?: 0's and 1's correspond to fully resolved SNPs, 2's come in pairs corresponding to
the genotype 2's and ?'s correspond to unconstrained SNPs. For each 2 in each template we
introduce a 0-1-variable y and a constraint binding it with the variable y’ corresponding to the
complimentary 2:
y + y’ = 1

Instead of completely resolving templates, we can resolve only 2's. Then several
haplotypes can fit partially resolved templates and at least one of the corresponding xvariables should be set to 1. This results in the following constraint: For any y-

assignment of 2's in each template T,

∑

x _ fits_ all_ y'_in_template_T

x ≥1+ ∑yi + | I1 | +∑(1− yi )− | I2 |
i∈I1

(2.7)

i∈I2

We should guarantee that each template is resolved. This is done by the following
constraint: For each template T ,

∑x ≥1

(2.8)

x _ fits_ template_ T

2.4.4

Experimental Study of ILP and Greedy Methods

In this section we compare our greedy and ILP based methods suggested in Section 2.4.1 with
previously

known

phasing

methods

such

as

Phamily

[27],

PHASE[95]

and

HAPLOTYPER[41] applied to phasing and missing recovery on family trio data. We first
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describe the test data sets then give experimental results of five methods for phasing and
then for missing data recovery of family trio data.
Our algorithms are evaluated on real and simulated data. The data set collected by Daly et
al. [138] is derived from the 616 kilobase region of human Chromosome 5q31 that may
contain a genetic variant responsible for Crohn disease by genotyping 103 SNPs for 129
trios. The missing data in this genotype data is about 16%. The data set was partitioned [138]
into eleven blocks with only a few common haplotypes inside.
The another real data set is collect by Gabriel et al. [81]. This data consists of genotypes
of SNPs from 62 region. We use population D which contains of 30 trois from Yoruba. This
data set contains about 10% missing data.
The simulated data is generated using ms [84], a well-known haplotype generator based on
the coalescent model of SNP sequence evolution. The ms generator emits a haplotype
population for the given number of haplotypes, number of SNPs, and the recombination
rate. We have simulated Daly et al. [138] data by generating 258 populations, each
population with 100 individuals and each haplotype with 103 SNPs, then randomly choosing
one haplotype from each population. We only simulate parents' haplotypes, then we obtain
family trio haplotypes and genotypes by random matching the parental haplotypes.
It is clear how to validate a phasing method on simulated data since the underlying
haplotypes are known. The validation on real data is usually performed on the trio data.
E.g., a phasing method is applied to parents (respectively, to children) genotypes and the
resulted haplotypes are validated on children's (respectively, on parents') genotypes.
Unfortunately, in our case, one can not apply such validation since a trio phasing method
may rely on both children and parents' genotypes. Therefore, we suggest to validate trio phasing
by erasing randomly chosen SNP values and recording the errors in the erased SNP sites. In
Tables 2.2, 2.3, 2.4, each row corresponds to an instance of real data (Daly et al. or Gabriel
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et al.) or simulated data (ms) and the column (E) shows the percent of erased data (0% no data erased, 1%-10% - percent of SNP values erased) .
The value of phasing errors is measured by the Hamming distance from the method's

solution to the closest feasible phasing. In Tables 2.2 and 2.3, for parents (P) we report
the percent of SNP values that should be inverted out of the total number of SNP values

that should be inferred (i.e., number of 2 plus number of unknown values). For children (C),
we report the percent of SNP which should be inverted with respect to the total number of
SNPs. The total number of errors (T) is the percent of SNP's that should be inverted in
order to obtain a feasible phasing solution.

Table 2.2 The results for five phasing methods on the real data sets of Daly et al.[138]
and Gabrile et al. [81] and on simulated data. The second column corresponds to the ratio of
erased data. The C corresponds to the error of child. The P corresponds to the error of parents.
The T corresponds to the total error.

In Table 2.3, we also report true error for phasing simulated genotype data which is the
Hamming distance between inferred and actual simulated underlying haplotypes for children
(C), for parents (P) and the total error (T).
Table 2.4 compares five methods (ILP, Greedy, Phamily, PHASE and HAPLOTYPER) on
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trio missing data recovery on the real data sets (Daly [138] and Gabriel [81]) and simulated
data. We erase random data in trio genotypes with certain amount (1%; 2%; 5% and 10%)
of the entire data. Instead, We report the error as the number of incorrectly recovered
erased positions of the genotypes on child (C*), parents (P*) and trios (T*) divided the total
number of erased positions in parent genotypes in percentage. We count only half error if
the compared paired SNP is 2 and 0 (or 1).

Table 2.3 The results for five phasing methods on the simulated data sets. The column E
represents the percent of erased data. The C corresponds to the true error of child. The P
corresponds to the true error of parents. The T corresponds to the true total error.

Table 2.4 The results for missing data recovery on the real and simulated data sets with five
methods. The second column corresponds to the ratio of erased data. The C* corresponds to
the error of child. The P* corresponds to the error of parents. The T* corresponds to the total
error.
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2.4.5 2SNP Phasing Method for Family Trios

We have enhanced 2SNP algorithm to phase family trio data. 2SNP trio phasing
have been compared with four other well-known phasing methods on simulated data
from [90]. 2SNP is much faster than all of them while loosing in quality only to
PHASE.
We have enhanced 2SNP algorithm as follows (see Figure 2.3). First we modify observed
haplotype frequencies F00, F01, F10, F11 with haplotype frequencies in 22's which can be
imputed from trio constraints. For example if we have three genotypes 22,01,22 (first parent,
second parent, and child) then we can impute first parent and child genotypes (10+01 and
01+10). Only positions with 2's in all three genotypes can be left unresolved. For these
genotypes we perform our standard estimation of P22 and C22.
The genotype graph g is constructed only for the children's genotypes. The edges
connecting resolved 2's are forced into MST by setting their weight to a large number.
Obtained maximum spanning tree uniquely determines the phasing of the corresponding
children's genotype. The parental haplotypes are inferred assuming no recombinations, i.e.,
one of the parental haplotypes is the haplotype transmitted to the child and another (nontransmitted) haplotype is complimentary.
If the parental genotype has a ? which can not be resolved from child's haplotypes, then
we keep ?'s in the complimentary haplotype. Finally, the left missing data are recovered the
same way as in Fig. 2.1.
For the family trios, the 2SNP is considerably faster than the 2SNP for the same trios if
they are assumed to be unrelated. Indeed, the size of each genotype graph is reduced and,
essentially, only children genotypes are phased.
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Figure 2.3 2SNP Trio Phasing Algorithm. The steps added to 2SNP phasing algorithm
are marked with +'s -- 3+, 4+, and 9+.
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2.4.6 Experimental Study of 2SNP for Family Trios

In this section we first describe the datasets and quality measures. Then, we compare
our 2SNP method with PHASE[96], HAP[83], HAP2[89], and PLEM[91] on simulated trio
data.
Error measures. A single-site error [96] is the percent of erroneous SNPs among all SNPs

in phased haplotypes. An individual error [91] is the percent of genotypes phased with at least
one error among all genotypes. A switching error [87] is the percent of switches (among
all possible switches) between inferred haplotypes necessary to obtain a true haplotype. For
each dataset we bootstraped phasing result 100 times, and for each bootstrap sample we
computed an error. The 95% confidence interval for the error mean was computed based on
the 100 error values.

Simulated data sets.

- ST1, ST2, ST3 - family trio data [93]: Trio datasets generated using a coalescent model
that incorporates variation in recombination rates and demographic events. Specific
simulation parameters used can be found in [94]. ST1 - 20 data sets of 30 trios
simulated with constant recombination rate across the region, constant population
size, and random mating.

Each of the 20 data sets consisted of 1 Mb of sequence.

ST2 - same as ST1, but with the addition of a variable recombination rate across
the region. ST3 - same as ST2, except a model of demography consistent with white
Americans was used.
Table 2.5 compares the 2SNP algorithm for family trios with PHASE[96], HAP[83],
HAP2[89], and PLEM[91]( The results for PHASE, HAP, HAP2, and PLEM are taken from
[90]) on simulated family trio datasets ST1, ST2, ST3. As for unrelated individuals, 2SNP is
much faster than other phasing methods. For ST1 is losing in switching error only to PHASE,
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for ST2 it loses to 3 methods, and for ST3 it loses to PHASE and HAP. This can be explained
by the fact that ST3 and especially ST2 strongly deviate from real datasets in the averaged odds
ratio λ .

Table 2.5 Comparison of 5 phasing methods on simulated trio data.

2.5

Conclusions

In conclusion, we have developed a new extremely fast and simultaneously highly
accurate phasing algorithm 2SNP based on 2-SNP haplotypes. We hope that it will be
very useful for high-throughput genotype data processing, e.g., SNP Mapping Arrays
(Affymetrix).
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CHAPTER 3
DISEASE ASSOCIATION SEARCH

Accessibility of high-throughput genotyping technology allows genome/chromosomewide association studies for common complex diseases.

This chapter addresses two

challenges commonly facing such studies [136]: (i) searching an enormous amount of possible
gene interactions and (ii) finding reproducible associations. These challenges have been
traditionally addressed in statistics [143] while here we apply computational approaches -optimization and permutation tests. A complex risk factor is modeled as a subset of SNP's
with specified alleles (MSC) and the optimization formulation asks for the one with the
minimum p-value or the maximum odds ratio. We have applied our search methods to real
case-control studies for several diseases (Crohn's disease [138], autoimmune disorder [163],
tick-born encephalitis [134], lung cancer [144], and rheumatoid arthritis [135]). Proposed
methods are compared favorably to the exhaustive search -- they are faster, find more
frequently statistically significant risk factors.

3.1

Introduction

Recent improvement in accessibility of high-throughput DNA sequencing brought a great
deal of attention to disease association and susceptibility studies. Successful genome-wide
searches for disease-associated gene variations have been recently reported [140, 144].
However, complex diseases can be caused by combinations of several unlinked gene
variations.
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This chapter addresses computational challenges of genotype data analysis in epidemiological
studies including selecting of informative SNPs, searching for diseases associated SNPs, and
predicting of genotype susceptibility.
Disease association studies analyze genetic variation across exposed to a disease
(diseased) and healthy (non-diseased) individuals. The difference between individual
DNA sequences occurs at a single-base sites, in which more than one allele is observed across population. Such variations are called single nucleotide polymorphisms
(SNPs). The number of simultaneously typed SNPs for association and linkage studies is reaching 106 for SNP Mapping Arrays [131]. High density maps of SNPs as well
as massive DNA data with large number of individuals and number of SNPs become
publicly available [156]. Diploid organisms, like human, have two near-identical copies
of each chromosome. Most genotyping techniques (e.g., SNP Mapping Arrays [131])
do not provide separate SNP sequences (haplotypes) for each of the two chromosomes.
Instead, they provide SNP sequences (genotypes) representing mixtures of two haplotypes -- each site is defined by an unordered pair of allele readings, one from each
haplotype -- while haplotypes are computationally inferred from genotypes [101]. To
genotype data we refer as unphased data and to haplotype data we refer as phased
data.

The disease association study analyze data given as genotypes or haplotypes

with disease status.
Several challenges in genome-wide association studies of complex diseases have not yet been
adequately addressed [137]: interaction between non-linked genes, multiple independent
causes, multiple testing adjustment, etc. Since complex common diseases can be caused by
multi-loci interactions two-loci analysis can be more powerful than traditional one-by-one SNP
association analysis [143]. Multi-loci analysis is expected to find even deeper diseaseassociated interactions. The computational challenge (as pointed in [137]) is caused by the
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dimension catastrophe. Indeed, two-SNP interaction analysis (which can be more powerful
than traditional one-by-one SNP association analysis [143]) for a genome-wide scan with 1
million SNPs (3 kb cover age) will afford 1012 possible pair wise tests. Multi-SNP interaction
analysis reveals even deeper disease-associated interactions but is usually computationally
infeasible and its statistical significance drastically decreases after multiple testing adjustment
[121, 125]

Disease association analysis searches for Risk Factors (RF) modeled as Multi-SNP
combinations with frequency among diseased individuals (cases) considerably higher
than among non-diseased individuals (controls).

Only statistically significant SNPs

(whose frequency distribution has p-value less than 0.05) are reported. Successful as
well as unsuccessful searches for SNPs with statistically significant association have
been recently reported for different diseases and different suspected human genome
regions (see e.g. [151]).

Unfortunately, reported findings are frequently not repro-

ducible on different populations. It is believed that this happens because the p-values
are unadjusted to multiple testing -- indeed, if the reported SNP is found among 100
SNPs then the probability that the SNP is associated with a disease by mere chance
becomes roughly 100 times larger.

3.1.1

Optimization Approach

This chapter discusses optimization approach to resolve these issues instead of traditionally
used statistical and computational intelligence methods. In order to handle data with huge
number of SNPs, one can extract informative (indexing) SNPs that can be used for (almost)
lossless reconstructing of all other SNPs[130]. To avoid information loss, index SNPs are
chosen based on how well the other non-index SNPs can be reconstructed. The
corresponding informative SNP selection problem (ISSP) can be formulated as follows

50
(See Figure 3.1). Given a sample S of a population P of individuals (either haplotypes or
genotypes) on m SNPs, select positions of k (k < m) SNPs such that for any individual, one
can predict non-selected SNPs from these k selected SNPs. The Multiple Linear Regression
based MLR-tagging algorithm

Figure 3.1 Informative SNP Selection Problem. The shaded columns correspond to k tag
SNPs and the clear columns correspond to non-tag SNPs. The unknown (m – k) non-tag
SNP values in tag-restricted individual (top) are predicted based on the known k tag values
and complete sample population.

[112] solves the optimization version of ISSP which asks for k informative SNPs minimizing
the prediction error measured by the number of incorrectly predicted SNPs. The number of
tags (informative SNPs) k depends on the desirable data size. More tags will keep more
genotype information while less tags allows deeper analysis and search.
In the reduced set of SNPs one can search for deeper disease association. In this
chapter we discuss the optimization problem of finding the most disease-associated multiSNP combination for given case-control data. Since it is plausible that common diseases can

have also genetic resistance factors, one can also search for the most disease-resistant multi-SNP
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combination. Association of risk or resistance factors with the disease can be measured in terms
of p-value of the skew in case and control frequencies, risk rates or odds rates. Here we first
concentrate on two association measurements: p-value of the skew in case and control
frequencies and positive predictive value (PPV) which is the frequency of case individuals
among all individuals with a given multi-SNP combination. This optimization problem is
NP-hard and can be viewed as a generalization of the maximum independent set problem. A fast
complimentary greedy search proposed in [133] is compared with the exhaustive search and
combinatorial search that has been discussed in [132]. Although complimentary greedy
search cannot guarantee finding of close to optimum MSCs, in the experiments with real
data, it finds MSCs with non-trivially high PPV. For example, for Crohn's disease data [138],
complimentary greedy search finds in less than second a case-free MSC containing 24 controls,
while exhaustive and combinatorial searches need more than 1 day to find case-free MSCs with
at most 17 controls.
We have applied our search methods (exhaustive, combinatorial and complimentary
greedy searches [132, 133], alternating combinatorial search and a randomized of
complimentary greedy search) for finding MSC with largest odds ratio on real case-control
studies for several diseases (Crohn's disease [138], autoimmune disorder [163], tick-born
encephalitis [134], lung cancer [144], and rheumatoid arthritis [135]). Proposed methods are
compared favorably to the exhaustive search -- they are faster, find more frequently
statistically significant risk factors.
We next model atomic risk factors (ARF's) (i.e., SNP risk factors that cannot be split into
simpler factors) for common diseases as diplotypes, i.e., subsets of SNP's with specified
alleles. Our first optimization formulations ask for a diplotype the most tightly associated with
the disease (i.e., minimizing p-value) [132] and having the highest positive predictive [133].
In contrast, epidemiologists measure the quality of risk factors in case-control studies by odds
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ratio defined as the ratio of the odds of disease occurring in the exposed (to the risk factor)
group to the odds of it occurring in unexposed group. Thus, we ask for an ARF with the
maximum odds ratio. We show connection of this problem with the known Red-Blue Set
Cover problem [166] whose special case is equivalent to the weighted set cover problem. The
best known heuristics for the weighted set cover problem is a well-known greedy algorithm.
Thus, in order to find ARF with the maximum odds ratio, we propose to apply the
complementary greedy search (CGS) algorithm [133] originally designed for finding ARF’s
with highest positive predictive value.
We next propose to consider more complex but also more relevant SNP risk factors, so called
k-relaxed atomic risk factors, for which exposed individuals can deviate in at most k sites
from a given diplotype. We generalize the complimentary greedy algorithm (k-CGS) to find
k-relaxed atomic risk factors with fixed k. Our experiments show advantage of the new
method over CGS in finding risk factors with significantly higher odds ratio and association
with the disease.
We then introduce even more general risk factors, so called weighted relaxed atomic
risk factors. The individuals exposed to such factors should be within weighted Hamming
distance k from a given diplotype. We also proposed a novel heuristic (WCGS) for finding
weighted relaxed ARF with odds ratio.
We have applied and cross-validated CGS [133], k-CGS, and WCGS methods for finding
atomic risk factors (ARF), k-relaxed ARF's and weighted relaxed ARF's, respectively,
with large odds ratios on real case-control studies for several diseases (Crohn's disease [138],
autoimmune disorder [163], tick-born encephalitis [134], lung cancer [144], and rheumatoid
arthritis [135]). The CGS algorithm finds non-trivially ARF’s with significantly high odds
ratios. For the smallest dataset (tick-born encephalitis) CGS found an optimal solution which
has been confirmed using an exact integer linear program. The k-CGS and WCGS methods
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found SNP risk factors that are statistically significant even after multiple-testing adjustment
on all data while CGS could not find significant ARF on two of these data. The found relaxed
atomic risk factors explain much higher number of cases, 1.5-4 times larger than atomic ARFs
found by CGS. The new methods also have significantly higher leave-half-out crossvalidation rate.

3.1.2

Overview

In the next section the disease association search problem is formulated, the searching
algorithms and their quality measures are described, the optimization version of disease
association search for most disease associated MSC is reformulated as an independent set
problem and the fast complimentary greedy search and randomized complimentary greedy
search algorithms are given. Then we formally introduce the problem of finding a risk factor
with maximum odds ratio and apply our searching methods to solve this problem. We further
model genetic RFs as atomic RFs (ARFs), then we generalize it to k-relaxed ARFs (kRARF) and weighted RARF (WRARF). For the introduced models we formulate
optimization problems and give heuristics for finding maximum odds ratio atomic, k-relaxed
atomic and weighted relaxed atomic risk factors, respectively. We next describe available real
datasets and conclude with comparison and cross-validation of described heuristics.

3.2

Methods for Disease Association Search

In this section the search of statistically significant disease-associated multi-SNP
combinations is formally described. Then the corresponding optimization problem is
formulated and its complexity is discussed. The combinatorial search introduced in [132]
and the fast complementary greedy search introduced in [133] are described.
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The typical case-control or cohort study results in a sample population S consisting of n
individuals represented by values of m SNPs and the disease status. Since it is expensive to
obtain individual chromosomes, each SNP value attains one of three values 0, 1 or 2, where
0's and 1's denote homozygous sites with major allele and minor allele, respectively, and 2's
stand for heterozygous sites. SNPs with more than 2 alleles are rare and can be conventionally
represented as biallelic. Thus the sample S is an (0, 1, 2)-valued n × (m + 1)-matrix, where
each row corresponds to an individual, each column corresponds to a SNP except last
column corresponding to the disease status (0 stands for case and 1 stands for control). Let H
and D be the subsets of rows with controls (healthy) and cases (disease), respectively.
The standard measure of disease association in case-control studies is the odds ratio (OR) –
the odds of a risk factor occurring in cases to the odds of it occurring in controls. Formally, let
C be the subset of genotypes of S exposed to a risk factor (further referred as a cluster) and let
h(C) = C ∩H be the set of controls and d(C) = C ∩ D be the set of cases in cluster C. Then the
odds ratio of a risk factor which forms cluster C is computed as
OR =

| d (C ) | / | d ( D − C ) |
| h (C ) | / | h ( H − C ) |

The odds ratio is ill-defined when |h(C)| = 0, i.e., when the corresponding cluster is control
free. In order to define and compare OR for such cases, we follow standard practice of adding
0.5 to all 4 values |d(C)|, |d(D - C)|, |h(C)|, |h(H - C)|.
The association of a risk factor with the disease status can be also measured with the
following parameters:

•

relative risk

RR = (| d (C ) | * | S − C |) (| D − d (C ) | * | C |) (for cohort studies)

positive predictive value PPV =| d (C ) | / | C | (for susceptibility prediction)
•

p-value of the partition of the cluster into cases and controls:
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p=

|d ( C )|

∑
k =0

⎛ | C | ⎞⎛ | D | ⎞
⎜⎜
⎟⎟⎜⎜
⎟⎟
⎝ k ⎠⎝ | S | ⎠

k

⎛| H |⎞
⎜⎜
⎟⎟
⎝ |S|⎠

|C |− k

A complex risk factor in SNP case-control study is modeled as a subset of SNP’s with
specified alleles (diplotype, multi-SNP combination (MSC)), and general disease association
searches for all risk factors with OR above (or below) a certain threshold. The common
formulation is to find all risk factors with p-value below 0.05. An optimization version can be
formulated as follows.
Most Associated Risk Factor Problem. Given a genotype case/control study on a sample

population S, find an risk factor most associated with the disease.
Since associated risk factors are searched among exponentially many risk factors (SNP
combinations), the computed p-value (significance) requires adjustment for multiple testing
(MT) which can be done with simple but overly pessimistic Bonferroni correction or
computationally extensive but more accurate randomization method. In our study we use
randomization method which computes the p-value of a risk factor by comparing its OR with
OR’s of 104 risk factors found by searching method on 104 randomized datasets. A randomized
dataset is obtained from original dataset by random swapping of the disease statuses. If OR of a
risk factor is larger than 9500 (95%) of OR’s from randomized datasets then the MT-adjusted
p-value of this risk factor is <5%.

3.2.1

Full Searches for Associated MSCs

Risk and resistance factors representing gene variation interaction can be defined in terms
of SNPs as a multi-SNP combination (MSC) which is a subset of SNP with fixed alleles
values. General disease association searches for all MSCs with one of the parameters above (or
below) a certain threshold. The common formulation is to find all MSCs with adjusted p-value
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below 0.05.

3.2.1.1

Exhaustive Search (ES)

The search for disease-associated MSCs among all possible combinations can be done by
the following exhaustive search. In order to find a MSC with the p-value of the frequency
distribution below 0.05, one should check all one-SNP, two-SNP, ..., m-SNP combinations.
⎛
m ⎛m⎞ k ⎞
The checking procedure takes runtime Ο⎜⎜ n∑k =1 ⎜⎜ ⎟⎟3 ⎟⎟ for unphased combinations
⎝k⎠ ⎠
⎝
since there are 3 possible SNP values {0, 1, 2}. Similarly, for phased combination, the
⎛
m ⎛m⎞ k ⎞
runtime is Ο⎜⎜ n∑k =1 ⎜⎜ k ⎟⎟3 ⎟⎟ since there only 2 possible SNP values. The exhaustive
⎝ ⎠ ⎠
⎝
search is infeasible even for small number of SNPs, therefore the search is limited to the
small number of SNPs, i.e., instead of searching all MSCs, one can search only containing
at most k = 1, 2, 3 SNPs. We refer to k as search level of exhaustive search. Also one can
reduce the depth (number of simultaneously interacting SNPs) or reduce m by extracting
informative SNPs from which one can reconstruct all other SNPs. The MLR-tagging is
used to choose maximum number of index SNPs that can be handled by ES in a reasonable
computational time.

3.2.1.2

Combinatorial Search (CS)

Here we discuss suggested in [132] search method for disease-associated MSCs which avoids
insignificant MSCs or clusters without loosing significant ones. CS searches only for closed
MSCs, where closure is defined as follows. The closure C of MSC with cluster C is an MSC
whose cluster has minimum control elements h( C ) and the same case elements d( C ) = d(C).

C can be easily found by incorporating into its set of SNPs all SNPs with common values
among all case individuals in C .
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The combinatorial search proposed [132] finds the best p-value of frequency distribution of
the closure of each single-SNP, after that it searches for the best frequency distribution pvalue among closure of all 2-SNP combinations and so on. The procedure stops after all
closure of all k-SNP combinations (k < m) are checked. The corresponding search level is
the number of SNPs selected for closuring, e.g., on the level 2 of searching combinatorial
search will test closure of all 2-SNP combinations for association with a disease. Because of
the closure, for the same level of searching combinatorial search finds better association than
exhaustive search. However, the above combinatorial search is as slow as exhaustive search.
A faster implementation of this method avoids checking MSCs which are not (and
cannot lead to) statistically significant ones. Formally, a MSC I is called an intersection
of MSCs with clusters C1 and C2 if d(I) = d(C1) ∩ d(C2) and |h(I )| is minimized. An MSC
is called trivial if its unadjusted p-value is larger than 0.05 even if the set h(C) would be
empty. Note that intersection of a trivial MSC with another is trivial.
A faster implementation of the combinatorial search is as follows:

1. Compute a set G1 of all 1-SNP closed MSCs, exclude trivial combinations.
2. Compute sets Gk of all pair wise intersections of the MSCs from Gk-1, exclude trivial
combinations and already existing in G1 Υ G 2 Υ...Υ G k −1 , k = 2..N .
3. For each Gk output MSCs whose unadjusted p< 0.05.
Still, in order to find all MSCs associated with a disease one has to check all possible SNP
combinations with all possible SNP values.

This searching approach is

also

computationally intensive and step 2 from the algorithm can generate an exponential
number of MSCs. However, closure avoids generation and checking of non-significant
MSCs. Additionally, removing of trivial MSCs at each iteration of step 2 considerably
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reduces the number of newly generated MSCs. CS has been shown much faster than ES
and capable of finding more significant MSCs than ES for equivalent search level.

3.2.1.3

Alternating Combinatorial Search (ACS)

This is a modification of CS which tries to further decrease the number of controls in a
cluster C obtained by CS repeatedly using the following alternating closing and
complimenting:

C ← (C − (C ∩ D))

These iterations stop as soon as C stops changing.

3.2.2

Maximum Control-Free Cluster

Following [133], we next consider another optimization formulation corresponding to the
general association search problem, e.g., find MSC with the minimum adjusted p-value. In
particular, we focus on maximization of PPV. Obviously, the MSC with maximum PPV
should not contain control individuals in its cluster and the problem can be formulated as
follows:
Maximum Control-Free Cluster Problem (MCFCP). Find a cluster C which

does not contain control individuals and has the maximum number of case individuals.
It is not difficult to see that this problem includes the maximum independent set problem.
Indeed, given a graph G = (V , E ), for each vertex v we put into correspondence a case
individual v’ and for each edge e = (u, v) we put into correspondence a control individual e’
such that any cluster containing u’ and v’ should also contain e’ (e.g., u’ , v’ , and e’ are
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identical except one SNP where they have 3 different values 0,1, and 2). Obviously, the
maximum independent set of G corresponds to the maximum control-free cluster and vice
versa. Thus, one cannot reasonably approximate MCFCP in polynomial time for an arbitrary
sample S. On the other hand, the sample S is not “arbitrary” -- it comes from a certain
disease association study. Therefore, one may have hope that simple heuristics (particularly
greedy algorithms) can perform much better than in the worst arbitrary case.

3.2.3

Maximum Odds Ratio Atomic Risk Factor

Since there are exponentially many genetic risk factors, in this section we concentrate only
on basic atomic risk factors. We then give the corresponding optimization formulations and
describe their relationship with the red-blue set cover problem. Finally, the complementary
greedy algorithm inspired by the greedy algorithm is described.
In general, an arbitrary SNP risk factor can be expressed as a boolean formula over
SNPs as follows. A genotype SNP value is a function over x and y which are SNP values
in haplotypes (0 and 1 in haplotypes stand for major and minor alleles, respectively). These
function are boolean -- a genotype equals 0 iff g 0 = x ∨ y is true, equals 1 iff g1 = x ∧ y is
true, and equals 2 iff g 2 = x ⊕ y is true. Then a risk factor is a disjunctive normal form
(DNF) over g0's, g1's and g2's for all SNPs. Substituting each negation with
g i = g i −1 ∨ g i +1 , i = 0,1,2 , we can make sure that DNF does not contain negations. An
atomic risk factor (ARF) corresponds to a single clause of DNF and cannot be further split
into simpler risk factors. An atomic risk factor may be also viewed as a diplotype which is a
subset of SNP-columns of S with fixed values.
An ARF can model multiple gene interactions resulting in a single cause of a disease (see
Figure 3.2 (a)) -- several pathways may result in generating a certain substance (e.g., protein) P
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necessary for a normal cell functions. Several mutations should cut all such pathways to
create a lack of P -- any pathway that is not destroyed by mutations can produce sufficient
amount of P preventing disease development.

wild type

mutation

(a) Atomic Risk

(b) 1-Relaxed Atomic Risk

(c) Weighted k-Relaxed Atomic Risk Factor

Figure 3.2 Pathway motivation of Atomic Risk Factors, k-Relaxed ARFs, and
Weighted Relaxed ARFs. (a) ARF models the case when all n pathways producing the
substance P should be broken by mutations to cause the disease. (b) k-RARF models the
case when it is necessary to have arbitrary k + 1 unaffected pathways out of total n pathways to
produce sufficient amount of P and, therefore, breaking of any (n - k) pathways causes the
disease. (c) WRARF models the same case as k-RARF but when different pathways can
produce different integer number w of units of P.
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Here we suggest to consider optimization formulation :
Maximum Odds Ratio Atomic Risk Factor (MORARF): Given a genotype

case-control study on a sample population S, find atomic risk factor with the maximum odds
ratio.
Our experiments with real and simulated genotype case-control studies showed
that the solution for the MORARF problem is usually control-free, i.e., for the
corresponding cluster C , h(C) = 0. The corresponding problem has been formulated in [133].
Maximum Control-Free Cluster (MCFC) Problem. Given a genotype case-control

study on a sample population S, find a maximum size control-free cluster C .
It has been shown in [133] that this problem contains the independent set problem and
therefore is NP-hard and is hard to approximate. Alternatively, instead of maximizing the
number of cases in the cluster we can pursue the complimentary objective -- minimize number
of cases outside of the cluster. The corresponding problem has been previously studied under
the name red-blue set cover problem [166].

Red-Blue Set Cover (RBSC) Problem. Given a set of “red” elements R, a set of

"blue" elements B and a family of subsets Φ ⊆ 2 R∪ B , find a subfamily X ⊆ Φ covering all
blue elements and minimizes the minimum number of covered red elements.
When searching MCFC, the red elements are cases and blue elements are controls. The
RBSC problem minimizes the number of red elements covered by a family of X while the
MCFC problem maximizes non-covered red elements. The difference between RBSC and
MCFC is the same as between the minimum vertex cover and maximum independent set
problems.
The complexity of the RBSC problem has been studied in [166]. They show that even the
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case where every set contains only one blue and two red elements cannot be approximated
1− δ

to within O (2 log

n

) , where δ = 1 / log log c n , for any constant c < 1/2 (where n = Φ ).

Unfortunately, the approximation algorithms proposed in [166] for RBSC do not have a
non-trivial bounds in the MCFC context.
If restrictions on R of all sets from Φ coincide or do not intersect then the RBSC
problem is equivalent to the weighted set cover problem where the cost of each set is equal to
the number of red elements in it. The best known approximation algorithm for the weighted
set cover problem is a well-known greedy algorithm.

3.2.3.1

Complimentary Greedy Search (CGS)

In graphs, instead of the maximum independent set one can search for its complement, the
minimum vertex cover -- repeat picking and removing vertices of maximum degree until no
edges left. In this case one can minimize the relative cost of covering (or removal) of control
individuals, which is the number of removed case individuals. The corresponding heuristic
for MCFCP and MORARF is the following
It can be inductively applied to the general RBSC problem -- iteratively choose the
next set minimizing the ratio of newly covered red elements over newly covered blue
element. This algorithm applied to the MCFC problem has been proposed in [133] as the
Complimentary Greedy Search (CGS) (see Figure 3.3). CGS iteratively adds SNP value
that minimizes the relative cost of removal of controls, where the cost is the number of
removed cases by the same SNP value.
CGS can be directly applied to the MORARF problem rather than to MCFCP -- at each
iteration update and output the diplotype with currently best OR. Our experiments show that
each iteration of CGS always improved OR for all real dataset although sometimes first
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iterations can slightly violate monotonicity for randomized (bootstrapped) data (see Figure
3.4).

Figure 3.3 Complimentary Greedy Search

Figure 3.4 The value of the odds ratio of atomic risk factors (with vertical bars
representing 95% confidence interval (CI)) on i-th iteration of complimentary greedy search
on lung-cancer dataset (see Section 2.4.4).
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Our experiments with several available real data sets (see Section 3.3) show that the
complimentary greedy search can find atomic risk factors with no-trivially high OR. For the
tick-borne encephalitis dataset (see Section 3.3.1) CGS found an optimal solution which has
been confirmed using an exact integer linear program. Similarly to the maximum control-free
cluster corresponding to the most expressed risk factor, one can also search for the maximum
diseased-free cluster corresponding to the most expressed resistance factor. The experiments
with three real data sets (see Section 3.3) show that the complimentary greedy search can find
nontrivially large control-free and case-free clusters.
It is known that randomization improves quality of greedy algorithms. In this paper,
we propose the following randomization enhancement of CGS

3.2.3.2

Randomized CGS (RCGS).

We expect randomization to change strictly greedy behavior of the CGS allowing to avoid
the local maximum.
Let Hi be a subset of controls S0 with indices 1,…i. RCGS (see Figure 3.5) repeatedly
permutes controls and gradually covers them with SNPs -- first it covers two
thirds of H ⎡e 2 ⎤ and then it covers two thirds of H ⎡e3 ⎤ and so on, finally on the iteration
covers the entire H. RCGS outputs the maximum OR atomic risk factor out of 100
runs. It also outputs several atomic risk factors in case if adjusted p-value of their ORs are
below 0.05. RCGS always finds risk factor with OR larger than OR of the risk factor found
by CGS. However, it is not always more significant after multiple testing adjustment.
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Experimental results (see Sections 3.3, 3.4) show that greedy heuristics are faster, find more
frequently statistically significant risk factors and have significantly higher cross-validation
rate.

Figure 3.5 Randomized Complimentary Greedy Search

Let Hi be a subset of controls S0 with indices 1,…i. RCGS (see Figure 3.5) repeatedly
permutes controls and gradually covers them with SNPs -- first it covers two
thirds of H ⎡e 2 ⎤ and then it covers two thirds of H ⎡e3 ⎤ and so on, finally on the iteration
covers the entire H. RCGS outputs the maximum OR atomic risk factor out of 100
runs. It also outputs several atomic risk factors in case if adjusted p-value of their ORs are
below 0.05. RCGS always finds risk factor with OR larger than OR of the risk factor found
by CGS. However, it is not always more significant after multiple testing adjustment.
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Experimental results (see Sections 3.3, 3.4) show that greedy heuristics are faster, find more
frequently statistically significant risk factors and have significantly higher cross-validation
rate.

3.2.4

Maximum Odds Ratio k-Relaxed and Weighted Relaxed Atomic
Risk Factors

In this section we give intuition and formally introduce a generalization of atomic risk
factors with potentially larger OR, so called k-relaxed atomic risk factors. We then
describe generalization of CGS to the problem of finding the k-relaxed atomic risk factor
with the largest odds ratio.
Below we give two different intuitions leading to the notion of k-relaxed atomic risk
factor. Recall that ARF models a single complex cause of a disease -- several simultaneous
mutations should cut all pathways producing a protein P (see Figure 3.2 (a)). Assume now
that several individual causes are closely related. This may happen if the disease is caused by
insufficient amount of a protein P rather than complete absence of P. Then breaking of
sufficiently many pathways (but not necessarily all of them) can cause a disease. For
example, Figure 3.2 (b) illustrates the case when out of 3 different pathways it is sufficient to
break any 2 to cause a disease.
On the other hand, in the Hamming metric space of all diplotypes, one can expect that
there exists a “representative" diplotype x associated with the disease that is completely
surrounded by other diplotypes having significantly high OR or being control-free. The
maximum radius ball around x consisting of diplotypes that are underrepresented in
controls corresponds to such a risk factor. We say that a genotype g is exposed to a krelaxed atomic risk factor (k-RARF) defined by an atomic risk factor with the diplotype x, if
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there are at most k SNPs in g mismatching corresponding SNPs in x. A cluster C of
individuals exposed to a k-RARF with the diplotype x is a set of all genotypes in S whose
restriction on all but k SNPs of x coincide with SNP-values in x.
Maximum Odds Ratio k-Relaxed Atomic Risk Factor (MORRARF)
Problem: Given a genotype case-control study on a sample population S and a positive

integer k, find a k-relaxed atomic risk factor with the maximum odds ratio.

3.2.4.1

k-Complimentary Greedy Search (k-CGS)

For the MORRAF problem, we have adjusted the complimentary greedy search applied
to the MORARF problem. The adjusted algorithm is called k-CGS (see Figure 3.6).

Figure 3.6 k-Complimentary Greedy Search (k-CGS)
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3.2.4.2

Weighted Complimentary Greedy Search (WCGS)

In this section we further relax k-relaxed ARF's to weighted relaxed ARF's, formulate
the corresponding optimization problem and give the corresponding complimentary greedy
algorithm.
Similarly to k-RARF, we give two intuitions leading to the notion of weighted

relaxed atomic risk factor.

Recall that k-RARF models the case when breaking of

sufficiently many pathways can cause a disease (see Figure 3.2 (b)). The weighted
relaxed ARF models the case when different pathways produce different amount of
the resulted protein P , and, therefore, different SNPs cancel different amount of P.
For example, Figure 3.2 (c) illustrates the case when the first pathway produces 3 units
of P while the second and the third pathways produce 1 and 2 units of P, respectively.
Therefore, a SNP breaking the first pathway already cancel 3 units of P and causes
a disease while breaking only the second or only the third pathway is not sufficient
to disease development.
On the other hand, in the Hamming metric space of all diplotypes, a ball around a
“representative” diplotype x consisting of diplotypes underrepresented may be stretched or
shrunk along different axes (SNPs). Formally, given a diplotype x with positive integer weight
ws for each SNP s in x, the w-weighted Hamming distance from a genotype g to x equals the
weighted number of mismatches between them, wh( g , x) = ∑ s∈x ws δ s , where δ s = 1 if
there is a mismatch in s and 0, otherwise. A cluster C of individuals exposed to a weighted
k-relaxed risk factor (WRARF) with the diplotype x and weights w on SNPs of s is a set of
all genotypes within w-weighted Hamming distance k from x.
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Figure 3.7 Weighted Complimentary Greedy Search

Weighted Complimentary Greedy Search (WCGS) on Figure 3.7 is a fast greedy
heuristic for finding maximum odds ratio WRARF. It consists of forward and backward
steps (see Figure 3.8). The forward step is similar to the iterations in CGS and k-CGS -it finds the best thresholds ks=v in Ss=v and ks≠v in Ss≠v , i.e., thresholds that reduce controls

paying the least amount of removed cases per control and equalizing these thresholds by
setting the weight to difference ks=v - ks≠v (see Figure 3.8 (a)). The backward step does not
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have analogy -- it increases the number of cases so that the number of added controls per case is
smaller than in the last forward step (see Figure 3.8 (b)). Whenever possible, WCGS makes
step backward and if it is impossible it makes the step forward.

CGS/k-CGS

WCGS
(∆D/∆H)Æmax
Step
∆D
∆H

∆H
(∆H/∆D)Æmax
step forward

∆D

(∆H/∆D)Æmax
step forward

∑

D = number of cases

D = number of cases

(a)

(b)

Figure 3.8 One greedy iteration of the CGS, k-CGS, and WCGS algorithms.

3.3

Experimental Results

In this section we discuss the results of methods for searching disease-associated multiSNP combinations and report the number of found statistically significant atomic risk

factors on real datasets. We first describe several datasets, then overview search methods and
conclude with description and discussion of their performance. All experiments were ran on
Processor Pentium 4 3.2Ghz, RAM 2Gb, OS Linux.
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3.3.1

Data Sets

- Crohn's disease (5q31): The data set Daly et al [138] is derived from the 616 kilobase region of
human Chromosome 5q31 that may contain a genetic variant responsible for Crohn's disease
by genotyping 103 SNPs for 129 trios. All offspring belong to the case population, while
almost all parents belong to the control population. In entire data, there are 144 case and 243
control individuals.
- Autoimmune disorder: The data set of Ueda et al [163] are sequenced from 330kb of human
DNA containing gene CD28, CTLA4 and ICONS which are proved related to
autoimmune disorder. A total of 108 SNPs were genotyped in 384 cases of autoimmune
disorder and 652 controls.
- Tick-borne encephalitis: The tick-borne encephalitis virus-induced dataset of Barkash et
al [100] consists of 41 SNPs genotyped from DNA of 21 patients with severe tickborne
encephalitis virus-induced disease and 54 patients with mild disease.
- Rheumatoid arthritis: dataset [135] represents a dense panel of 2300 SNPs genotyped by
Illumina for an approximately 10 kb region of chromosome 18q that showed evidence for
linkage in the U.S. and French linkage scans. These markers were individually genotyped on
460 cases and 460 controls. Controls were recruited from a New York City population.
- Lung cancer: dataset [144] was obtained using genome-wide DNA pooling strategy in a
group of German smokers clinically diagnosed with lung cancer and agematched healthy
smokers. 83.715 SNPs had beed screened. 141 SNPs showed putative allelic imbalance
between case and control DNA pools and were eventually genotyped in individual
samples. Finally, dataset includes 322 male smokers with lung cancer and 273 healthy
smokers genotyped in 141 SNPs.
- HapMap datasets: Regions ENr123 and ENm010 from 2 population: 45 Han Chinese from
Beijing (HCB) and 44 Japanese from Tokyo (JPT) for three regions (ENm013, ENr112,
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ENr113) from 30 CEPH family trios obtained from HapMap ENCODE Project [156].

Two gene regions STEAP and TRPM8 from 30 CEPH family trios were obtained from
HapMap.
The datasets have been phased using inhouse 2SNP software [101]. The missing data
(16% in [138] and 10% in [163]) have been imputed in genotypes from the resulted
haplotypes. We have also created corresponding haplotype datasets in which each individual
is represented by a haplotype with the disease status inherited from the corresponding
individual genotype.

3.3.2

Search Methods

Here we discuss the results of four methods for searching disease-associated MSCs
on real phased and unphased datasets. The p-values of the frequency distribution of
the found MSCs are used as a quality measurement. Then we report the number of
found statistically significant atomic risk factors by six proposed searching methods.
Search Methods. We have compared the following 5 methods for search diseaseassociated MSCs.
•

Exhaustive Search (ES)

•

Indexed Exhaustive Search (IES30): exhaustive search on the indexed datasets
obtained by extracting 30 indexed SNPs with MLR based tagging method [113]

•

Combinatorial Search (CS)

•

Indexed Combinatorial Search (ICS30): combinatorial search on the indexed
datasets obtained by extracting 30 indexed SNPs with MLR based tagging
method [113]

•

Complimentary Greedy Search (CGS): approximate search for the maximum
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control-free or maximum odds ration cluster and corresponding Atomic Risk Factor.
•

k-Relaxed Complimentary Greedy Search (k-CGS): approximate search for the
maximum odds ration k-Relaxed Atomic Risk Factor.

•

Weighted Complimentary Greedy Search (WCGS): approximate search for the
maximum odds ration Weighted k-Relaxed Atomic Risk Factor.

Significant MSCs have been found only on levels 1 and 2 because adjusted p-value grows
with the level.

The size of the datasets is enough large to make exhaustive search

impossible even for a combination of 6 SNPs.

3.3.3

Comparison of Full Searches

The quality of searching methods is compared by the number of found statistically significant
MSCs (see the 7th column) in genotypes (see Table 3.1) and haplotypes (see Table 3.2). Since
statistical significance should be adjusted to multiple testing, we report for each method and
data set the 0.05 threshold adjusted for multiple testing (this threshold is computed by
randomization and given in the third column of Tables 3.1 and 3.2). In the 3d, 4th and 5th
columns, we give the frequencies of the best MSC among case and control population and the
unadjusted p-value, respectively

3.3.4

Comparison of Approximate and Full Searches

We have compared IES30 and ICS30 with CGS (see Section 3.2) for search disease associated
multi-SNP combinations with the largest PPV.
The quality of searching methods is compared by the PPV of found clusters as well as
their statistical significance Table 3.3.
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Table 3.1 Comparison of 4 methods for searching disease-associated multi-SNPs
combinations for unphased genotype. Index value denote number of indexed SNPs.
datasets.

3.3.5

Significance of Found Atomic Risk Factors

The Table 3.4 compares search heuristics ES(1), CS(1), ACS(1) (1-level exhaustive,
combinatorial and alternating combinatorial searches), their 2-level counterparts, and CGS with
RCGS applied to all 5 real datasets. For (almost) all datasets the OR of methods are ordered
as follows: ES(1), CS(1), ES(2), ACS(1), CS(2), ACS(2), RCGS. The place of CGS is
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mostly between CS(2) and RCGS. The same order for heuristics holds for the lower limit of
95% CI of OR and unadjusted p-value. All methods except CGS also can report all found
atomic risk factors with multiple-testing adjusted p-value less than 5%. On the most of data
our new methods can find more statistically significant atomic risk factors. Note that ES,
CS, and ACS are much slow than greedy heuristics.

Table 3.2 Comparison of 4 methods for searching disease-associated multi-SNPs
combinations for phased genotype. Index value denote number of indexed SNPs. datasets.
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Table 3.3 Comparison of three methods for searching the disease-associated and diseaseresistant multi-SNPs combinations with the largest PPV. The starred values refer to results of
the runtime-constrained exhaustive search

Figure 3.9 shows the results of CGS, k-CGS, and WCGS algorithms after each iteration.
The results are shown for all available datasets except autoimmune disorder datset. For this
dataset results are similar to the results for rheumatoid arthritis (see Figure 3.9 (b)). The plots
in the Figure 3.9 should be read from right to left. The top-right corner corresponds to the
starting point of each algorithm. The bottom axis corresponds to the stopping point. The
algorithm for best method stops with the largest number of cases in the cluster. For all
compared datasets the OR of RFs found by the methods are ordered as follows: CGS, k-CGS,
WCGS. The WCGS finds clusters by 1.5 to 4 times larger than CGS.
Table 3.5 compares 3 search heuristics applied to all 5 real datasets. For k-CGS method
we consider k = 5, that is the best found value of k which fits all 5 datasets. The third column
in the table shows that for all datasets CGS is outperformed by k-CGS which is inferior to
WCGS when compared to the number of cases in the cluster formed by found RF
(equivalent to maximum OR). The forth column shows the multiple testing adjusted p-value
of the found RFs. The k-CGS finds statistically more significant RFs than CGS and WCGS
finds even more significant RFs.
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Table 3.4 Comparison of 5 methods searching atomic risk factors represented by multi-SNP
combinations on five real datasets. For accurate search methods the number in parenthesizes
denote searching level.

78

450

WCGS

number of controls

240

400
350

200

5-CGS

300

160

250

CGS

120

200
150

80

100

40

50

0

0

0

50

100

150

200

250

300

0

50

100

150

200

(a)

250

300

350

400

450

(b)
240

number of controls

60

210
180

45

150
120

30

90
60

15

30
0

0
0

5

10

15

number of cases

(c)

20

25

0

20

40

60

80

100

120

140

number of cases

(d)

Figure 3.9 Number of cases and controls in the cluster after each iteration of CGS, k-CGS,
and WCGS algorithms run on 4 datasets: (a) - lung cancer, (b) rheumatoid arthritis, (c) - tickborne encephalitis, (d) - Crohn's disease. Starting point corresponds to the top-right corner
where clusters contains entire S . Algorithms stop when number of controls in the cluster is
zero (bottom axis).

Table 3.5 Comparison of CGS, k-CGS, and WCGS methods for searching ARF, k-ARF, and
WRARF with maximum OR cluster on five real datasets.
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For datasets of Crohn's disease [138] and autoimmune disorder [163] WCGS finds significant
WRARFs while no other methods were able to find anything significant. The number of
SNPs in the diplotypes corresponding to RFs are presented in the fifth column. The last
column in the Table 3.5 shows the runtime of each method.

3.4

Cross-Validation of Searching Methods

This section addresses problems of validation of methods searching for disease associated
risk factors in genotype data analysis.
This challenge is of statistical nature. Only statistically significant risk factors (whose
frequency distribution has p-value less than 0.05) are believed to be reproducible.
Successful as well as unsuccessful searches for SNPs with statistically significant association
have been reported for different diseases and different suspected human genome regions (see,
e.g., [136]). Unfortunately, reported findings are frequently not reproducible in independent
case-control studies. It can be caused by confounding factors or the lack of significance -the reported p-values are frequently unadjusted to multiple testing. Nevertheless, validation
of findings on independent data is usually very expensive and additional evidence may
help.

Still it would be preferable to estimate how frequently a search method finds

reproducible MSC. Here we propose to directly validate searching methods using crossvalidation scheme, i.e., in the same way as predictions are validated.
We have cross-validated our search methods on real case-control studies for several diseases

(Crohn's disease [138], autoimmune disorder [163], tick-born encephalitis [134], and lung
cancer [144]). Proposed methods are compared favorably to the exhaustive search -- they

80
have significantly higher leave-half-out cross-validation rate.

3.4.1

Permutation Test for Multiple-Testing Adjustment

Since statistically significant MSCs are searched among many such combinations, the
computed p-value requires adjustment for multiple testing. The standard Bonferroni correction
adjusts p-value by multiplying it by the number of the number of tests, i.e., number of tested
MSCs. However, the Bonferroni correction is overly pessimistic, e.g., for finding one
significant SNP among 100 we should multiply its p-value by 100; as a result, SNP should have
p < 0.0005 in order to be statistically significant. Similarly, this factor grows to 104 for 2SNP combinations. Instead, we compute multiple testing adjustment using more accurate but
computationally extensive randomization method. 104 times, we repeat the following:
1. randomize the status of individuals (by random swapping);
2. find the 500th smallest p-value of MSCs.

This p-value corresponds to the multiple testing adjusted p = 0.05.

3.4.2
3.4.2.1

Experimental Results
Data Sets

- Crohn's disease (5q31): The data set Daly et al [138] is derived from the 616 kilobase region of
human Chromosome 5q31 that may contain a genetic variant responsible for Crohn's disease
by genotyping 103 SNPs for 129 trios. All offspring belong to the case population, while
almost all parents belong to the control population. In entire data, there are 144 case and 243
control individuals.
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- Autoimmune disorder: The data set of Ueda et al [163] are sequenced from 330kb of
human DNA containing gene CD28, CTLA4 and ICONS which are proved related to
autoimmune disorder. A total of 108 SNPs were genotyped in 384 cases of autoimmune
disorder and 652 controls.

Table 3.6 Leave-half-out cross-validation of 4 disease-association search methods on 4 real
datasets. The validation rate for a method is the portion of MCS found on the training half
that have been validated (i.e., have p-value < 5%) on the testing half. The significance
rate is the portion of MSC on the training half that stay significant after multiple testing
adjustment. For accurate search methods the number in parenthesizes denote searching level.

- Tick-borne encephalitis: The tick-borne encephalitis virus-induced dataset of Barkash et al
[100] consists of 41 SNPs genotyped from DNA of 21 patients with severe tick-borne
encephalitis virus-induced disease and 54 patients with mild disease.
- Lung cancer : dataset [144] was obtained using genome-wide DNA pooling strategy in a
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group of German smokers clinically diagnosed with lung cancer and age matched healthy
smokers. 83.715 SNPs had beed screened. 141 SNPs showed putative allelic imbalance
between case and control DNA pools and were eventually genotyped in individual
samples. Finally, dataset includes 322 male smokers with lung cancer and 273 healthy
smokers genotyped in 141 SNPs.

3.4.2.2

Leave-Half-Out Cross-Validation of Searching Methods

The Table 3.6 describes the results of leave-half-out cross-validation which has been
organized as follows: 100 times we randomly choose one half of cases and one half of controls
for the training set keeping the rest for the testing set. The table reports two rates:
- the validation rate for a method is the portion of MCS found on the training half that

have been validated (i.e., have p-value < 5%) on the testing half;
- the significance rate is the portion of MSC on the training half that stay significant after
multiple testing adjustment.
All methods have low validation rate but greedy heuristics on all sets are more
frequently validated. Also the greedy heuristics frequently find significant risk factors while
ES also finds a lot of significant factors that are rarely validated on testing data.
Only statistically significant risk factors (whose frequency distribution has p-value less than
0.05) are believed to be reproducible. Nevertheless, validation of findings on independent
data is usually very expensive and additional evidence may help. However, it would be
preferable to estimate how frequently a search method finds reproducible RFs. He we
directly validate searching methods using cross-validation scheme, i.e., in the same way as
predictions are validated.
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In Table 3.7 WCGS is compared favorably to the CGS -- it finds statistically significant risk factors more frequently and has significantly higher 2-fold cross-validation
rate.

Table 3.7 Validation of CGS and WCGS on 3 real datasets. The 2-fold crossvalidation column corresponds to % best RFs on the training half validated on testing
half (p-value < 5%). The random-validation columns is the same but testing is allowed
to overlap with training. The significance corresponds to % best RFs on the training
half significant after MT-adjustment. The double significance column shows % of best
RFs on the training half significant after MT-adjustment that are also significant on
the testing half.

3.5

Conclusions

Comparing indexed counterparts with exhaustive and combinatorial searches shows that
indexing is quite successful. Indeed, indexed search finds the same MSCs as nonindexed search
but it is much faster and its multiple-testing adjusted 0.05-threshold is higher and easier to
meet.
Comparing combinatorial searches with the exhaustive counterparts is advantageous to
the former. Indeed, for unphased data [138] the exhaustive search on the first and second search
levels is unsuccessful while the combinatorial search finds several statistically significant
MSCs for the same searching level. Similarly, for unphased and phased data of [163] the
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combinatorial search found much more statistically significant MSCs than the exhaustive
search for the same searching level.
Results show (see Tables 3.6 and 3.2) that the indexing approach and the combinatorial
search method are very promising techniques for searching statistically significant diseasesassociated MSCs which can lead to discovery disease causes. The next step is biological
validation of statistically significant MSCs discovered by proposed searching methods.
The comparison of three association searches (see Table 3.3) shows that combinatorial search always finds the same or larger cluster than exhaustive search and is
significantly faster. The search method runtime is a critical in deciding whether it can be
used in in clustering and susceptibility prediction. Note that the both exhaustive and combinatorial searches are prohibitively slow on the first two datasets and, therefore,
we reduce these datasets to 30 index SNPs while complementary greedy search is fast enough
to handle the complete datasets. This resulted in improvement of the complementary greedy
over combinatorial search for the first dataset when search for the largest case-free cluster after compression to 30 tags the best cluster simply disappears.
On the most of data our new methods can find more statistically significant atomic risk
factors. Note that ES, CS, and ACS are much slow than greedy heuristics. All methods
have low validation rate but greedy heuristics on all sets are more frequently validated. Also
the greedy heuristics frequently find significant risk factors while ES also finds a lot of
significant factors that are rarely validated on testing data.
The k-CGS and WCGS are significant improvement over CGS since they found risk
factors that are statistically significant even after multiple-testing adjustment on all data
while CGS could not find significant ARF on two of these data (see Table 3.5). The found
relaxed atomic risk factors explain much higher number of cases, 1.5-4 times larger than
atomic ARFs found by CGS. The k-CGS and WCGS methods also have significantly
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higher leave-half-out crossvalidation rate (see Table 3.7).
We conclude that the indexing approach, the combinatorial and complementary greedy
search methods as well as k-Relaxed and Weighted k-Relaxed CGS are very promising
techniques that can possibly help (i) to discover gene interactions causing common diseases
and (ii) to create diagnostic tools for genetic epidemiology of common diseases.
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CHAPTER 4
DISEASE SUSCEPTIBILITY PREDICTION

This chapter explores possibility of applying discrete optimization methods to predict the
genotype susceptibility for complex disease. We propose two approaches for
predicting genotype susceptibility: (i) universal classifier combinatorial approach and
(ii) association based combinatorial approach. The proposed combinatorial method have
been favorably compared with existing methods on several publicly available
genotype data.

4.1

Introduction

Recent improvement in accessibility of high-throughput genotyping brought a great
deal of attention to disease association and susceptibility studies [165]. High density maps
of single nucleotide polymorphism (SNPs) [156] as well as massive genotype data with large
number of individuals and number of SNPs become publicly available[153, 154, 157]. A
catalogue of all human SNPs is hoped to allow genome-wide search of SNPs associated with
genetic diseases.
Success stories when dealing with diseases caused by a single SNP or gene were reported.
But some complex diseases, such as psychiatric disorders, are characterized by a non mendelian,
multifactorial genetic contribution with a number of susceptible genes interacting with each
other [161, 147]. In general, a single SNP or gene may be impossible to associate because a
disease may be caused by completely different modifications of alternative pathways.
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Furthermore, there are no reliable tools applicable to large genome ranges that could rule out
or confirm association with a disease. It is even difficult to decide if a particular disease is
genetic, e.g., the nature of Crohn's disease has been disputed [146]. Although answers to
above questions may not explicitly help to find specific disease-associated SNPs, they may be
critical for disease prevention. Indeed, knowing that an individual is (or is not) susceptible to
(or belong to a risk group for) a certain disease will allow greatly reduce the cost of
screening and preventive measures or even help to completely avoid disease development, e.g.,
by changing a diet.

4.1.1

Universal Classifier Approaches

This study is devoted to the problem of assessing accumulated information targeting to
predict

genotype

susceptibility

accuracy and statistical power.

to

complex

diseases

with

significantly

high

We first give several discrete optimization based

algorithms for prediction disease susceptibility.

We then compare leave-one- and

leave-many-out tests demonstrating that prediction accuracy of suggested methods
is sufficiently resilient to discarding case-control data implying that leave-one-out
test is a trustworthy accuracy measure.

The randomization techniques have been

used for computing the statistical significance level of proposed methods and resulted
prediction weights. We show that prediction rate and statistical significance are well
correlated.
The proposed methods are applied to two publicly available data: Crohn's disease [153] and
autoimmune disorder [163]. In the leave-one-out cross-validation tests the proposed linear
programming (LP) based method achieves prediction rate of 69.5%(p-value below 2%) and
61.3%(p-value below 62%) and the risk rates of 2.23 and 0.98, respectively. We also show that
SVM methods used in [159, 164] are not much worse than our proposed LP-based method.
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4.1.2

Association Based Combinatorial Approaches

The second part of the chapter shows how to apply association search methods to
disease susceptibility prediction following [133]. First the problem and cross-validation
schemes are discussed. Then the relevant formulation of the optimum clustering problem is
given and the general method how any clustering algorithm can be transformed into a
prediction algorithm is described. We conclude with description of two association searchbased prediction algorithms.
Below is the formal description of the problem from [133].
Disease Susceptibility Prediction Problem (DSP). Given a sample population S
(a training set) and one more individual t ∉ S with the known SNPs but unknown
disease status (testing individual), find (predict) the unknown disease status.

The main drawback of such problem formulation that it cannot be considered as a
standard optimization formulation. One cannot directly measure the quality of a prediction
algorithm from the given input since it does not contain the predicted status.
A standard way to measure the quality of prediction algorithms is to apply a crossvalidation scheme. In the leave-one-out cross-validation, the disease status of each genotype
in the population sample is predicted while the rest of the data is regarded as the training set.
There are many types of leave-many-out cross-validations where the testing set contains much
larger subset of the original sample. Any cross-validation scheme produces a confusion table
(see Table 4.1). The main objective is to maximize prediction accuracy while all other
parameters also reflect the quality of the algorithm.
The next section formally defines the problem and describes several universal and ad hoc
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methods for predicting genotype susceptibility to complex diseases. Section 4.3 introduces
our LP-based prediction algorithm. Then we introduce an optimum disease clustering
problem and describe association based combinatorial methods for disease susceptibility
prediction.
Section 4.6 describes real case-control study data sets, discusses prediction and risk rate
measures and compares results for several susceptibility prediction methods. We draw the
conclusion in the last section.

4.2

Previous Work

In this section we first describe the input and the output of prediction algorithms and
how to predict genotype susceptibility. We the describe several universal and adhoc
prediction methods.
Specifications of prediction algorithms. Data sets have n genotypes and each has m

SNPs. The input for a prediction algorithm includes:

(G1) Training genotype set gi = (gi,j ); i = 0,.., n – 1, j = 1,.., m, gi,j ∈ {0, 1, 2}
(G2) Disease status s(gi) ∈ {-1, 1}, indicating if gi, i = 0,.., n - 1, is in case (1) or in control
(-1) , and

(G3) Testing genotype gn without any disease status.
The input data can also be phased, then each genotype is represented by a pair of
haplotypes. We will refer to the parts (G1-G2) of the input as training set and to the part
(G3) as the test case. The output of prediction algorithms is the disease status of the genotype
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gn, i.e., s(gn ).
Below we describe several universal prediction methods. These methods are adaptations of
general computer-intelligence classifying techniques.
Closest Genotype Neighbor (CN). For the test genotype gt, find the closest (with respect

to Hamming distance) genotype gi in the training set, and set the status s(gt) equal to s(gi).
Support Vector Machine Algorithm (SVM). Support Vector Machine (SVM) is a

generation learning system based on recent advances in statistical learning theory. It maps input
vectors to a higher dimensional space where a maximal separating hyperplane is
constructed. Then 2 parallel hyperplanes are constructed on each side of the
hyperplane that separates the data. The separating hyperplane is the hyperplane that
maximises the distance between the two parallel hyperplanes. An assumption is
made that the larger the margin or distance between these parallel hyperplanes the
smaller the classification error is. SVMs deliver state-of-the-art performance in real-

world applications and have been used in case/control studies [159, 164]. We use SVM-light
[150] with the radial basis function with γ= 0.5.
Random Forest (RF). A random forest is a collection of CART-like trees following

specific rules for tree growing, tree combination, self-testing, and post-processing. We use
Leo Breiman and Adele Cutler's original implementation of RF version 5.1 [148]. This
version of RF handles unbalanced data to predict accurately. RF tries to perform regression on
the specified variables to produce the suitable model. RF uses bootstrapping to produce
random trees and it has its own cross-validation technique to validate the model for
prediction/classification.
CDPG: Tomita [162] introduced the Criterion of Detecting Personal Group (CDPG) for

extracting risk factor candidates (RFCs). RFCs are extracted using binomial test and random
permutation tests. CDPG performs exhaustive combination analysis using case/control
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data and assumes the appearance of case and control subjects belonging to a certain rule as a
series of Bernoulli trials, where two possible outcomes are case and control subjects with some
probabilities.
We now describe two ad hoc prediction methods (i.e., classifying techniques taking in
account the nature of the classification problem). The first method is 2-SNP method

[158] and the second method is a variation of the LP-based method [160].
Most Reliable 2 SNP Prediction [158] (MR). This method chooses a pair of

adjacent SNPs (site of si and si+1) to predict the disease status of the test genotype gt by
voting among genotypes from training set which have the same SNP values as gt at the
chosen sites si and si+1. They chose the 2 adjacent SNPs with the highest prediction rate in
the training set.

4.3

LP-based Prediction Algorithm (LP).

This method are based on the following genotype graph X = {H, G}, where the vertices
H are distinct haplotypes and the edges G are genotypes each connecting its two haplotypes
(vertices) (see Figure 4.1(a)).
When applying graph heuristics to X, we found that it is necessary to increase the
density of X. This can be achieved by dropping certain SNPs (or, equivalently, keeping only
certain tag SNPs). Indeed, dropping a SNP may result in collapsing of certain vertices in X,
i.e., different vertices become identical. Collapsing vertices may also result in collapsing certain
edges (genotypes). Discarding a SNP is not allowed if it results in collapsing edges from case
and control populations, but collapsing of edges from the same population is allowed (see
Figure 4.1(b)).
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Figure 4.1 LP-based Prediction Method. (a) The set of case, control and test genotypes
are phased resulting in the sparse graph with vertices-haplotypes and edges genotypes. (b) The last
two SNPs are dropped without collapsing case and control edges resulting in a denser graph.
(c) The LP finds optimal weights for vertices haplotypes. (d) The status of test genotypes is
predicted from the sign of the sum of weights of their endpoints.

A simple greedy strategy consists of traversing all the SNPs and dropping a SNP
if it is allowed. The resulted set of SNPs is a minimal subset of SNPs which do not
collapse genotypes from opposite disease status. Unfortunately, in the original graph
X we may already have collapsed edges from opposite populations - in fact, Daly
et al data contain such pair of genotypes.

Only such original collapsing is allowed

-- the status of such edges is assumed to be the one of majority of genotypes. Our
experiments show that on average, we are left with 21 tag SNP's out of 103 for Daly
et al [153] data and 29 tag SNP's out of 108 for Ueda et al [163] data (see description
of the next section). The selected set tag SNPs are better candidates for being disease
associated, in fact only such tag SNPs were used in the prediction methods with the
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highest accuracy.
After collapsing the graph X we add the edge corresponding to the test-case
genotype gn. If the edge gn collapses with another edge gi, then we set the predicted
disease status s(gn) = s(gi). Otherwise, we apply one of the following two methods
for computing the disease status s(gn). The LP-based method assumes that certain
haplotypes are susceptible to the disease while others are resistant to the disease.
The genotype susceptibility is then assumed to be a sum of susceptibilities of its two
haplotypes.
We want to assign a positive weight to susceptible haplotypes and a negative weight to
resistant haplotypes such that for any control genotype the sum of weights of its haploptypes
is negative and for any case genotype it is positive (see Figure 4.1 (c)). We would also like
to maximize the confidence of our weight assignment which can be measured by the
absolute values of the genotype weights. In other words, we would like to maximize the
sum of absolute values of weights over all genotypes.
Formally, for each vertex hi (corresponding to haplotype) of the graph X we wish to
assign the weight pi, -1 < pi <1 such that for any genotype-edge eij = (hi, hj ), s(eij )(pi

+pj) ¸ 0 where s(eij) ∈ {-1, 1} is the disease status of genotype represented by edge eij .
The total sum of absolute values of genotype weights is maximized

∑ s(e )( p + p )

eij =( hi , h j )

ij

i

j

(4.1)

The above formulation with the objective (4.1) is the linear program which can be
efficiently solved by a standard linear program solver such as GNU Linear Programming
Kit (GLPK) [155].

94
For the left-out testing genotype gn, we compute the sum of weights of its haplotypes. If
the sum is strictly positive, the genotype is attributed to the case, if the sum is strictly
negative, it is attributed to the control (see Figure 4.1(d)), otherwise s(gn) is assigned
according to 2-SNP prediction algorithm [158].

4.4

Optimum Disease Clustering Problem

Here we proposes to avoid cross-validation and instead suggests a different objective by restricting the ways how prediction can be made. It is reasonable to require
that every prediction algorithm should be able to predict the status inside the sample.
Therefore, such algorithms is supposed to be able to partition the sample into subsets
based only on the values of SNPs, i.e., partition of S into clusters defined by MSCs.
Of course, a trivial clustering where each individual forms its own cluster can always
perfectly distinguish between case and control individuals. On the other hand such
clustering carries minimum information.

Ideally, there should be two clusters per-

fectly distinguishing diseased from control individuals. There is a trade-off between
number of clusters and the information carried by clustering which results in trade-off
between number of errors (i.e., incorrectly clustered individuals) and informativeness
which was proposed to measure by information entropy instead of number of clusters
[133].

Optimum Disease Clustering Problem. Given a population sample S, find a

partition P of S into clusters S = S1 ∪ .. ∪ S k , with disease status 0 or 1 assigned to each
cluster Si, minimizing
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k

| Si | | Si |
ln
|S|
i =1 | S |

entropy ( P ) = − ∑

for a given bound on the number of individuals who are assigned incorrect status in clusters
of the partition P, error(P) < α * |P|.
The above optimization formulation is obviously NP-hard but has a huge advantage over
the prediction formulation that it does not rely on cross-validation and can be studied with
combinatorial optimization techniques. Still, in order to make the resulted clustering
algorithm useful, one needs to find a way ho to apply it to the original prediction problem.

4.5

Model-Fitting Prediction

The following general approach has been proposed by us [133]. Assuming that the
clustering algorithm indeed distinguishes real causes of the disease, one may expect that the
major reason for erroneous status assignment is in biases and lack of sampling. Then a plausible
assumption is that a larger sample would lead to a lesser proportion of clustering errors. This
implies the following transformation of clustering algorithm into prediction algorithm:
Clustering-based Model-Fitting Prediction Algorithm

Set disease status 0 for the testing individual t and
Find the optimum (or approximate) clustering P0 of S ∪ {t}
Set disease status 1 for the testing individual t and
Find the optimum (or approximate) clustering P1 of S ∪ {t}
Find which of two clusterings P0 or P1 better fits model, and accordingly predict status of t,
status (t ) = arg(min i =0,1 error ( Pi ))
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Two clustering algorithms based the combinatorial and complementary greedy association
searches has been proposed in [133]. This clustering finds for each individual an MSC or its
cluster that contains it and is the most associated according to a certain characteristic (e.g.,
RR, PPV or lowest p-value)) with disease-susceptibility and disease-resistance. Then each
individual is attributed the ratio between these two characteristic values -- maximum
disease-susceptibility and disease-resistance. Although the resulted partition of the training
set S is easy to find, it is still necessary to decide which threshold between case and control
clusters should be used. The threshold can be chosen to minimize the clustering error.
The combinatorial search-based prediction algorithm (CSP) exploits combinatorial search
to find the most-associated cluster for each individual. Empirically, the best association
characteristic is found to be the relative risk rate RR. The complimentary greedy search-

based prediction algorithm (CGSP) exploits complimentary greedy search to find the mostassociated cluster for each individual. Empirically, the best association characteristic is found
to be the positive predictive value PPV. The leave-one-out cross-validation (see Section 4.6.3)
show significant advantage of CSP and GCSP over previously known prediction algorithms
for all considered real datasets.

4.6

Experemental Study

In this section we discuss the results of methods for susceptibility prediction on real
datasets. We first describe available real datasets, then overview search and prediction
methods and conclude with description and discussion of their performance on leave-one-out
and leave-many-out cross-validation tests. All experiments were ran on Processor Pentium 4
3.2Ghz, RAM 2Gb, OS Linux.
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4.6.1

Data Sets

- Crohn's disease (5q31): The data set Daly et al [138] is derived from the 616 kilobase region of
human Chromosome 5q31 that may contain a genetic variant responsible for Crohn's disease
by genotyping 103 SNPs for 129 trios. All offspring belong to the case population, while
almost all parents belong to the control population. In entire data, there are 144 case and 243
control individuals.

- Autoimmune disorder: The data set of Ueda et al [163] are sequenced from 330kb of human
DNA containing gene CD28, CTLA4 and ICONS which are proved related to
autoimmune disorder. A total of 108 SNPs were genotyped in 384 cases of autoimmune
disorder and 652 controls.

- Tick-borne encephalitis: The tick-borne encephalitis virus-induced dataset of Barkash et al
[100] consists of 41 SNPs genotyped from DNA of 21 patients with severe tickborne
encephalitis virus-induced disease and 54 patients with mild disease.
The datasets have been phased using 2SNP software [101]. The missing data (16% in
[138] and 10% in [163]) have been imputed in genotypes from the resulted haplotypes. We
have also created corresponding haplotype datasets in which each individual is represented
by a haplotype with the disease status inherited from the corresponding individual genotype.

4.6.2

Results for Universal Classifiers Methods

Cross-validation Tests. In the leave-one-out cross-validation, the disease status of each

genotype in the data set is predicted while the rest of the data is regarded as the training set.
In the leave-many-out cross-validation, n individuals are uniformly at random picked up

98
from the data set, marked and put back, where n is the size of the data set. This way,
approximately 2/3 of the individuals are picked at least once and marked while the rest will
not be marked. The training set consists of marked data and the testing set consists of
unmarked data.

Table 4.1 Confusion table

Quality Measures. In cross-validation tests, the predicted and the actual disease statuses

are compared and the standard confusion matrix is filled (see Table 4.1). We report sensitivity,
specificity, and accuracy of the prediction methods. We also report the the risk rate of the
corresponding integrated risk factor associated with each prediction method. It is
computed as the the ratio of the probability of developing disease among those predicted
susceptible to the probability of developing disease among those predicted non-susceptible
[152]:

Risk _ Rate =

TP
FN
/
TP + FP TN + FN
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We report the 95% confidence intervals (CI) for accuracy and risk rate, for leaveone-out test 95% CI is computed using bootstrapping. We also compute significance
level, p-value, for the accuracy of prediction algorithms computed using 5000 randomized instances. On the randomized instances, the average prediction rate for SVM and
RF

has

been

60%

and

for

all

other

methods

except

has

been

50%.

Results. Table 4.2 compares 6 different prediction methods for both data sets. Column C
denotes performed cross-validation tests, LOO stays for leave-one-out test and LMO
stays for leave-many-out test. For leave-one-out test, the best accuracy is achieved by LP
-- 69.5% on Daly et al. [153] data and by MR -- 63.9% on Ueda et al. [157]

data.

For

leave-many-out test, the accuracy only slightly degrades showing resiliency to the size of the
data. The risk rates for the integrated risk factor associated with prediction methods are
comparable with risk rates for individual SNPs -- for the first data set, 2.23 (LP method) vs
2.7 and for the second data set, 1.73 (RF method) and 1.64 (MR method) vs 3.2. The good
performance of SVM and certain other universal methods indicate that they can possibly be
adjusted to improve specific ad hoc methods for prediction of susceptibility to complex
diseases.
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Table 4.2 The comparison of sensitivity, specificity, accuracy and risk rate with 95%
confidence intervals (CI) and p-value for 6 prediction methods for two real data sets.
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4.6.3

Results for Association Based Prediction Methods

We compare the prediction algorithms based on combinatorial and complimentary greedy
searches (see Section 3.2.3.1) from previous chapter [133] with three universal classifiers
prediction methods. We have chosen SVM, RF, and LP since they have best prediction
results for two real data sets [138] and [163] (see Table 4.2).
Table 4.3 reports comparison of all considered prediction methods. Their quality is
measured by sensitivity, specificity, accuracy and runtime. Since prediction accuracy is the
most important quality measure, it is given in bold.1 Figure 4.2 shows the receiver operating
characteristics (ROC) representing the trade-off between specificity and sensitivity. ROC is
computed for all five prediction methods applied to the tick-borne encephalitis data [100].

4.7

Conclusions

In this chapter, we discuss motivation behind the genotype susceptibility studies. The
proposed susceptibility prediction method based on linear programming is shown to have
high prediction rates and high relevant risk rate for associated integrated risk factors for two
completely different case-control studies for Crohn's disease [153] and autoimmune disorders
[157].
The comparison of the proposed association search-based and previously known
susceptibility prediction algorithms (see Table 4.3) shows a considerable advantage of new
methods. Indeed, for the first dataset the best proposed method (CGSP) beats the
previously best method (LP) in prediction accuracy 76.3% to 69.5%. For the second dataset,
the respective numbers are 74.2% (CSP(30)) to 65.1% (RF), and for the third dataset, they
are 80.3% (CSP) to 75.5% (LP). It is important that this lead is the result of much
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higher sensitivity of new methods -- the specificity is almost always very high since all
prediction methods tend to be biased toward non-diseased status.

Table 4.3 Leave-one-out cross validation results of four prediction methods for three real
data sets. Results of combinatorial search-based prediction (CSP) and complimentary
greedy search-based prediction (CGSP) are given when 20, 30, or all SNPs are chosen as
informative SNPs.
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The ROC curve also illustrates advantage of CSP and GCSP over previous methods.
Indeed the area under ROC curve for CSP is 0.81, for SVM is 0.52 compared with random
guessing area of 0.5. Another important issue is how proposed prediction algorithms
tolerate data compression. The prediction accuracy (especially sensitivity) is increases for
CGSP when more SNPs are made available -- e.g., for the second dataset, the sensitivity grows
from 29.4% (20 SNPs) to 32.3% (30 SNPs) to 46.3% (all 108 SNPs).

Figure 4.2 The receiver operating characteristics (ROC) for the five prediction methods
applied to the tick-borne encephalitis data [100]. All SNPs are considered tags for CGSP and
CSP.

The extensive computational results show great potential of the proposed association
search based susceptibility prediction algorithms.
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CHAPTER 5

SOFTWARE PACKAGES

1.

2SNP: fast and scalable phasing software for trios and unrelated individuals, based on

2-SNP haplotypes, http://alla.cs.gsu.edu/~software/2SNP.

2.

DACS: software for searching statistically significant multi-SNP combinations

associated with a disease and predicting disease susceptibility of a given individual,

http://alla.cs.gsu.edu/~software/DACS.

3.

TrioPhasing: integer linear programming based software for phasing Trio data,

requires LP solver, http://alla.cs.gsu.edu/»software/trioPhasing.html.

4.

GeneSuscept: software for predicting disease susceptibility. It implements LP-

based prediction algorithm.
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CHAPTER 6

FUTURE WORK

In our future work we concentrate on six challenges arising in disease-association and
disease-susceptibility prediction studies (i) design of more robust, fast and scalable algorithms
for disease association search, (ii) development of faster algorithms for adjusting to the
multiple testing the significance of the risk factors, (iii) developing of fast and acceptable
methods for validation of disease association search methods, (iv) developing of the scalable
indexing methods for genome-wide study, (v) design and testing of several disease models,
(vi) development of faster, scalable and more accurate disease susceptibility prediction
methods.
In the current work we had addressed the challenge of developing fast and
scalable methods for disease association search (see chapter 3) and several good

solutions had been proposed. The complimentary greedy search method (CGS) and its
randomized implementation (RCGS) give very impressive results by finding the significant
risk factors on the case-control study datasets where no associations were found before. Some
of those risk factors had been confirmed by independent biological studies. The CGS method is
very fast and scalable. However, it is too straightforward, and for several datasets, was
unable to find risk factors significantly associated with a disease while slower RCGS found
some of them. The problem with RCGS is that it is not scalable for genome-wide study.
Therefore, one of our future goals is speeding-up of the RCGS method by limiting its
randomness. We plan to implement randomization process using simulated annealing
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We also plan to develop new searching methods for wide-genome scan. These

methods will localize the DNA segments that possibly contain markers associated with a
disease. Then on the extracted pieces of DNA we can run our exhaustive combinatorial search
to find the multi-SNP combinations which mark disease.
When the disease-association methods will be accurate enough, we will move to our next
goal which is development of many disease models and their evaluation on different
diseases using our search methods. Successful models will allow us to understand how
complex diseases are embedded within the DNA.
The models which we will first analyze consider multiplicative and additive
integration of SNPs in forming complex risk factors for a complex diseases. In

chapter 3 we search for a risk factor associated with a disease modeled as an MSC,
i.e., set of SNPs with fixed allele values (multiplicative integration). However, the same
disease can be partially explained by several MSCs. Therefore, we should also consider
additive integration of MSCs. The next question arisen in model selection is haplotypes
or genotypes are basis of the disease causes.

One of the next goals is the design of the indexing methods which will allow us to
reduce large datasets to smaller ones without losing markers which marks disease. In the
reduced set we will be able to run more robust but slow searching methods. Currently we
use MLR-Tagging method (see chapter 3) for indexing which helps to perform deeper
disease association search. However, this method is not extendable for wide-genome scan
study.
The next challenge that we address in our future work is design of the fast methods for computing the significance of the risk factors. The significance of the risk

factor should be adjusted to the multiple testing by considering the total number of risk factors among which the search was performed and the complexity of the searching
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method. Currently we use permutation test which is very slow and completely useless for
medium or large datasets. For large datasets we have to perform Bonferroni adjustment which
is overly pessimistic and might disregard significant risk factors. Therefore, there is a great
need for a method that adjusts the significance in more accurate than Bonferroni way and it is
fast and scalable.
The next challenge which we address in our future work is methods for validation of
searching methods. Because of the lack of available genotype case-control study data and

their small size there no established methods for validation of the disease-association
search methods. In chapter 3 we propose to use cross-validation schemes usually applied for
prediction methods. However, this method is not very well tested and could be significantly
modified in our future research.
Based on the new developed searching methods we address in our future work the challenge
of developing of faster, scalable and more accurate disease susceptibility prediction
methods. The methods described in chapter 4 are acceptably accurate but extremely

slow for large datasets. Therefore, there is a great need for faster disease susceptibility
prediction methods.

108

CHAPTER 7
RELATED PUBLICATIONS

Refereed Journal Articles and Book Chapters

1. Brinza, D., He, J., and Zelikovsky, A. (2007) `Optimization Methods for Genotype Data

Analysis in Epidemiological Studies', book chapter in Bioinformatics Algorithms:
Techniques and Applications, January 2007.

2. Brinza, D. and Zelikovsky, A. (2007) `2SNP: Scalable Phasing Method for Trios and

Unrelated Individuals', Journal of IEEE/ACM Transactions on Computa tional Biology
and Bioinformatics (TCBB), invited, January 2007.

3. Brinza, D. and Zelikovsky, A. (2006) `2SNP: Scalable Phasing Based on 2-SNP

Haplotypes', BIOINFORMATICS , Pub 2006 Feb 1;22(3):371--373. Epub 2005 Nov 15.

4. Brinza, D., He, J., Mao, W. and Zelikovsky, A. (2005) `Family Trio Phasing and

Missing Data Recovery', International Journal Bioinformatics Research and
Applications, IJBRA'05 Vol. 1, No.2 pp. 221--229.

109

Refereed Conference Articles
5. Brinza, D. and Zelikovsky, A. (2007) `Design and Validation of Methods Searching

for Risk Factors in Genotype Case-Control Studies', The Third RECOMB Satellite
Conference on SNPs and Haplotype Analysis (SNPHAP 2007).
6. Brinza, D. and Zelikovsky, A. (2006) `Combinatorial Analysis of Disease Associ ation and

Susceptibility for Rheumatoid Arthritis SNP Data', Proc. of Genetic Analysis Workshop
(GAW15), 13:6--11.
7. Andre R. de Vries, Ilja M. Nolte, Geert T. Spijker, Dumitru Brinza, Alexander

Zelikovsky, and Gerard J. te Meerman (2006) `Cross Haplotype Sharing Statis tic:
Haplotype length based method for whole genome association testing', Proc. of Genetic
Analysis Workshop (GAW15), 13:16--21.
8. Brinza, D., He, J. and Zelikovsky, A. (2006) `Combinatorial Search Methods for Multi-

SNP Disease Association', Proc. International Conf. of the IEEE Engineering in
Medicine and Biology (EMBC'06), pp. 5802--5805.
9. Brinza, D. and Zelikovsky, A. (2006) `Combinatorial Methods for Disease Association

Search and Susceptibility Prediction', 6th Workshop on Algorithms in BioInformatics
(WABI 2006), Lecture Notes in Bioinformatics 4175, pp. 286--297.
10. Brinza, D., Perelygin, A., Brinton, M. and Zelikovsky, A. (2006) `Search for multi-

SNP Disease Association', The Fifth International Conference on Bioinformatics of
Genome Regulation and Structure (BGRS'06), pp. 122-125.
11. Brinza, D. and Zelikovsky, A. (2006) `Phasing of 2-SNP Genotypes based on Non-

Random Mating Model', International Workshop on Bioinformatics Research and
Applications (IWBRA'06), Proc. of ICCS 2006, LNCS 3992, pp.767-774.

110
12. Mao, W., Brinza, D., Hundewale, N., Gremalschi, S. and Zelikovsky, A. (2006)

`Genotype Susceptibility and Integrated Risk Factors for Complex Diseases', Proc. IEEE
Intl Conf on Granular Computing (GRC 2006), pp. 754--757.
13. Altun, G., Hu, H.-J., Brinza, D., Harrison, R.W., Zelikovsky, A. and Pan, Y. (2006)

`Hybrid SVM kernels for protein secondary structure prediction', Proc. IEEE Intl Conf
on Granular Computing (GRC 2006), pp. 762--765.
14. Mao, W., He, J., Brinza, D. and Zelikovsky, A. (2005) `A Combinatorial Method for

Predicting Genetic Susceptibility to Complex Diseases', International Conference of the
IEEE Engineering In Medicine and Biology Society (EMBC'05), pp. 224--227.
15. Brinza, D., He, J., Mao, W. and Zelikovsky, A. (2005) `Phasing and Missing Data

Recovery in Family Trios', International Workshop on Bioinformatics Research and
Applications (IWBRA'05),Proc. of ICCS 2005 LNCS 3515, pp.1011--1019.

Poster and Oral Presentations

1. Brinza, D. and Zelikovsky, A. (November 2006) `Case(Control)-Free Multi-SNP

Combinations in Case-Control Studies', Algorithmic Biology 2006, at University of
California, San Diego.

2. Brinza, D. and Zelikovsky, A. (November 2006) `Combinatorial Analysis of Disease

Association and Susceptibility for Rheumatoid Arthritis SNP Data', Genetic Analysis
Workshop 15, St Pete Beach, FL.

3. Brinza, D. and Zelikovsky, A. (October 2006) `Combinatorial methods for disease

association search and susceptibility prediction', Proc. of 9-th Conference of
Computational Genomics (CG'06), Baltimore, MD.

111
4. Brinza, D., He, J. and Zelikovsky, A. (September 2006) `Combinatorial Search Methods

for Multi-SNP Disease Association', International Conf. of the IEEE Engineering in
Medicine and Biology (EMBC'06), New-York, NY.

5. Barkhash, A., Perelygin, A., Brinza, D., Pilipenko, P., Bogdanova, YU.,

Romaschenko, A., Voevoda, M. and Brinton, M. (July 2006) `GENETIC
RESISTANCE TO FLAVIVIRUSES', Genomics Proteomics Bioinformatics and

Nanotechnologies for Medicine (GPBM'06), Novosibirsk, RU.

6. Brinza, D. and Zelikovsky, A. (Jun 2006) `Combinatorial Search Methods for

Genotypes Associated with Lung Cancer', Mollecular Basis of Disease Symphosium
(MBD'06), Atlanta, GA.

7. Barkhash, A., Perelygin, A., Brinza, D., Pilipenko, P., Bogdanova, YU.,

Romaschenko, A., Voevoda, M. and Brinton, M. (May 2006) `VARIABILITY IN
THE 2-5 OLIGOADENYLATE SYNTHETASE (OAS) GENE CLUSTER IS
ASSOCIATED WITH SEVERITY OF TICK-BORNE ENCEPHALITIS VIRUS-

INDUCED DISEASE IN RUSSIAN PATIENTS', 9-th Southeastern Regional Virology
Conference 2006, Atlanta, GA.

8. Brinza, D. and Zelikovsky, A. (November 2005) `2SNP: New Scalable Phasing Method',

The Fifth Georgia TECH International Conference on Bioinformatics (GTICB'05),
Atlanta, GA.

9. Brinza, D. and Zelikovsky, A. (October 2005) `2SNP: New Scalable Phasing
Method', The Second SECABC Fall Workshop ON Biocomputing (SECABC'05),

Atlanta, GA.

112
10. Brinza, D. and Zelikovsky, A. (August 2005) `New 2-SNP Statistics method for Phasing

and Missing data recovery', Georgia State Biotech Symposium, Atlanta, GA.

11. Brinza, D., He, J., Mao, W. and Zelikovsky, A. (May 2005) `Family Trio Phasing and

Missing Data Recovery', Research in Computational Molecular Biology (RECOMB'05),
Boston, MA.

113
BIBLIOGRAPHY

[1]

V. Bafna, D. Gusfield, G. Lancia, and S. Yooseph. Haplotyping as perfect
phylogeny: A direct approach. Technical report, UC Davis, Department of Computer
Science, 2002.

[2]

V. Bafna, D.Gusfield, G. Lancia, and S. Yooseph. Haplotyping as perfect
phylogeny: A direct approach. J. Computational Biology, 10:323--340, 2003.

[3]

R. E. Bixby and D. K. Wagner. An almost linear-time algorithm for graph
realization. Mathematics of Operations Research, 13:99--123, 1988.

[4]

R.H. Chung and D. Gusfield. Empirical exploration of perfect phylogeny
haplotyping and haplotypers. In Proceedings of COCOON 03 The 9'th International
Conference on Computing and Combinatorics, volume 2697 of LNCS, pages 5--19,
2003.

[5]

R.H. Chung and D. Gusfield. Perfect phylogeny haplotyper: Haplotype inferral using
a tree model. Bioinformatics, 19(6):780--781, 2003.

[6]

A. Clark. Inference of haplotypes from PCR-amplified samples of diploid
populations. Mol. Biol. Evol, 7:111--122, 1990.

[7]

A. Clark, K. Weiss, and D. Nickerson et. al. Haplotype structure and population
genetic inferences from nucleotide-sequence variation in human lipoprotein lipase.
Am. J. Human Genetics, 63:595--612, 1998.

[8]

M. Daly, J. Rioux, S. Schaffner, T. Hudson, and E. Lander. High resolution
haplotype structure in the human genome. Nature Genetics, 29:229--232, 2001.

114
[9]

P. Donnelly. Comments made in a lecture given at the DIMACS conference on
Computational Methods for SNPs and Haplotype Inference, November 2002.

[10]

E. Eskin, E. Halperin, and R. Karp. Large scale reconstruction of haplotypes from
genotype data. Proceedings of RECOMB 2003, April 2003.

[11]

E. Eskin, E. Halperin, and R. Karp. Efficient reconstruction of haplotype structure
via perfect phylogeny. Technical report, UC Berkeley, Computer Science Division
(EECS), 2002.

[12]

M. Fullerton, A. Clark, Charles Sing, and et. al. Apolipoprotein E variation at the
sequence haplotype level: implications for the origin and maintenance of a major
human polymorphism. Am. J. of Human Genetics, pages 881--900, 2000.

[13]

Gabriel, G., Schaffner, S., Nguyen, H., Moore, J., Roy, J., Blumenstiel, B.,

Higgins, J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S., Rotimi, C.,
Adeyemo, A., Cooper, R., Ward, R., Lander, E., Daly, M. and Altshuler, D.

(2002). The structure of haplotype blocks in the human genome. Science, 296:22252229.

[14]

D. Gusfield. Inference of haplotypes from samples of diploid populations: complexity
and algorithms. Journal of computational biology, 8(3), 2001.

[15]

D. Gusfield. Haplotyping as Perfect Phylogeny: Conceptual Framework and Efficient
Solutions (Extended Abstract). In Proceedings of RECOMB 2002: The Sixth
Annual International Conference on Computational Biology, pages 166--175,2002.

[16]

E. Halperin and E.Eskin. Haplotype reconstruction from genotype data using
imperfect phylogeny. Bioinformatics. Advance Access published on February 26, 2004.

115
[17]

R. Hudson. Gene genealogies and the coalescent process. Oxford Survey of Evolutionary
Biology, 7:1--44, 1990.

[18]

S. Lin, D. Cutler, M. Zwick, and A. Cahkravarti. Haplotype inference in random
population samples. Am. J. of Hum. Genet., 71:1129--1137, 2003.

[19]

T. Niu, Z. Qin, X. Xu, and J.S. Liu. Bayesian haplotype inference for multiple
linked single-nucleotide polymorphisms. Am. J. Hum. Genet, 70:157--169, 2002.

[20]

S. Orzack, D. Gusfield, and V. Stanton. The absolute and relative accuracy of
haplotype inferral methods and a consensus approach to haplotype inferral. Abstract
Nr 115 in Am. Society of Human Genetics, Supplement 2001.

[21]

Patil, N., Berno, A., Hinds, D., Barrett, W., Doshi, J., Hacker, C., Kautzer, C., Lee,
D., Marjoribanks, C., McDonough, D., Nguyen, B., Norris, M., Sheehan, J., Shen, N.,
Stern, D., Stokowski, R., Thomas, D., Trulson, M., Vyas, K., Frazer, K., Fodor, S.
and Cox, D. (2001). Blocks of limited haplotype diversity revealed by high-resolution
scanning of human chromosome 21. Science, 294, 171923.

[22]

M. Stephens, N. Smith, and P. Donnelly. A new statistical method for haplotype
reconstruction from population data. Am. J. Human Genetics, 68:978--989, 2001.

[23]

D.Brinza, J.He, W.Mao, and A.Zelikovsky (2005) `Family trio phasing and missing
data recovery', Proc. International Workshop on Bioinformatics Research and
Application (IWBRA'05).

[24]

Kimmel,G. and Shamir,R. (2005) `GERBIL: Genotype resolution and block
identification using likelihood', Proceedings of the National Academy of Sciences ,
102: 158-162.

116
[25]

Zhang, K., Calabrese, P., Nordborg, M., Sun, F. (2002) `Haplotype block structure
and its applications in association studies: power and study design', The American
Journal of Human Genetics, 71: 1836--1894.

[26]

Forton, J., Kwiatkowski, D., Rockett, K., Luoni, G., Kimber, M. and Hull
J.(2005) `Accuracy of haplotype reconstruction from haplotype-tagging

singlenucleotide polymorphisms', Am. J. Hum. Genet., 76(3):438-48.
[27]

Ackerman, H. et al (2003) `Haplotypic analysis of the TNF locus by association
efficiency and entropy', Genome Biology, 4:R24.

[28]

Brown, D.G. and Harrower, I.M. (2004) `A new integer programming formulation for
the pure parsimony problem in the haplotype association', Workshop on
Algorithms in Bioinformatics, v.3240, 3-540-23018-1

[29]

Clark, A. (1990) `Inference of haplotypes from PCR-amplified samples of diploid
populations', Mol. Biol., Evol, 7:111--122.

[30]

Daly, M., Rioux, J., Schaffner, S., Hudson, T. and Lander, E. (2001)
`Highresolution haplotype structure in the human genome', Nature Genetics, 29:229-

-232.
[31]

Gabriel, G., Schaffner, S., Nguyen, H., Moore, J., Roy, J., Blumenstiel, B.,

Higgins, J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S., Rotimi, C.,
Adeyemo, A., Cooper, R., Ward, R., Lander, E., Daly, M. and Altshuler, D.

(2002) `The structure of haplotype blocks in the human genome', Science, 296:22252229.

[32]

Gusfield, D. (2003) `Haplotype inference by pure parsimony', In R. Baeza-Yates, E.

117
Chavez, and M. Chrochemore,ed. 14'th Annual Symposium on Combinatorial Pattern
Matching, v. 2676 of Springer LNCS, 144--155.
[33]

Halperin, E. and Eskin, E. (2004) `Haplotype reconstruction from genotype data using
imperfect phylogeny', Bioinformatics, 20(12):1842-9.

[34]

Halperin, E. and Karp, R.M. (2003) `Large Scale Reconstruction of Haplotypes from
Genotype Data', International Conference on Research in Computational Molecular
Biology, 104--113.

[35]

Halperin, E. and Karp, R.M. (2004) `Perfect phylogeny and haplotype assignment',
International Conference on Research in Computational Molecular Biology, 1-58113755-9.

[36]

Hudson, R. (1990) `Gene genealogies and the coalescent process', Oxford Survey of
Evolutionary Biology, 7:1--44.

[37]

He, J. and Zelikovsky, A. (2004) `Linear Reduction for Haplotype Inference',
Proc. Workshop on Algorithms in Bioinformatics, September 2004, Lecture
Notes in Bioinformatics, 3240:242-253.

[38]

He, J. and Zelikovsky, A. (2004) `Linear Reduction Methods for Tag SNP
Selection', Proc. International Conf. of the IEEE Engineering in Medicine and
Biology, 2840-2843.

[39]

Li, J. and Jiang, J. (2003) `Efficient Rule-Based Haplotyping Algorithm for Pedigree
Data. In Proc.', International Conference on Research in Computational Molecular
Biology, 197-206

[40]

Lin, S., Chakravarti, A. and Cutler, D.J. (2004) `Haplotype and Missing Data

118
Inference in Nuclear Families', Genome Res,14(8):1624-32.
[41]

Niu, T., Qin, Z., Xu, X. and Liu, J.S. (2002) `Bayesian haplotype inference for
multiple linked single-nucleotide polymorphisms', Am. J. Hum. Genet, 70:157--169.

[42]

Stephens, M., Smith, N. and Donnelly, P. (2001) `A new statistical method for

haplotype reconstruction from population data', Am. J. Human Genetics, 68:978-989.
[43]

Avi-Itzhak, H.I., Su, X. and de la Vega, F.M. (2003) `Selection of minimum
subsets of single nucleotide polymorphism to capture haplotype block diversity',

Proceedings of Pacific Symposium on Biocomputing, Vol. 8, pp. 466--477.
[44]

Bafna, V., Halldorsson, B.V., Schwartz, R.S., Clark, A.G. and Istrail, S. (2003)
`Haplotypes and informative SNP selection algorithms: don't block out
information', Proceedings of the Seventh International Conference on Research in
Computational Molecular Biology, pp. 19--27.

[45]

Brinza, D., He, J., Mao, W. and Zelikovsky, A. (2005). `Phasing and Missing data
recovery in Family', International Workshop on Bioinformatics Research and
Applications (IWBRA 2005).

[46]

Carlson, C.S., Eberle, M.A., Rieder, M.J., Yi, Q., Kruglyak, L. and Nickerson,
D.A. (2004) `Selecting a maximally informative set of single-nucleotide
polymorphisms for association analyses using linkage disequilibrium', American
Journal of Human Genetics, Vol. 74, No. 1, pp. 106--120.

[47]

Clark, A., Weiss, K., Nickerson, D., Taylor, S., Buchanan, A., Stengard, J.,

Salomaa, V., Vartiainen, E., Perola, M., Boerwinkle, E., et al. (1998) `Haplotype

119
structure and population genetic inferences from nucleotide-sequence variation in
human lipoprotein lipase', American Journal of Human Genetics, Vol. 63, pp. 595-612.
[48]

Clark, A. (2003) `Finding genes underlying risk of complex disease by linkage
disequilibrium mapping', Current Opinion in Genetics & Development, Vol. 13, No.
3, pp. 296--302.

[49]

Chapman, J.M., Cooper, J.D., Todd, J.A. and Clayton, D.G. (2003). `Detecting
disease associations due to linkage disequilibrium using haplotype tags: a class of tests
and the determinants of statistical power', Human Heredity, Vol. 56, pp. 18--31.

[50]

Daly, M., Rioux, J., Schaffner, S., Hudson, T. and Lander, E. (2001) `High

resolution haplotype structure in the human genome', Nature Genetics, Vol. 29, pp.
229--232.
[51]

Eskin, E., Halperin, E. and Karp, R. (2003) `Efficient reconstruction of haplotype
structure via perfect phylogeny', Journal of Bioinformatics and Computational
Biology, Vol. 1, No. 1, pp. 1--20.

[52]

Forton, J., Kwiatkowshi, D., Rockett, K., Luoni, G., Kimber, M. and Hull, J.

(2005) `Accuracy of Haplotype Reconstruction from Haplotype-Tagging SingleNucleotide Polymorphisms', American Journal of Human Genetics Vol. 76, pp 438-448.
[53]

Halldorsson, B.V., Bafna, V., Lippert, R., Schwartz, R., de la Vega, F.M., Clark,
A.G. and Istrail, S. (2004) `Optimal haplotype block-free selection of tagging
SNPs for genome-wide association studies', Genome Research Vol. 14, pp. 1633--1640.

120
[54]

He, J. and Zelikovsky, A. (2004) `Linear Reduction Methods for Tag SNP
Selection', Proceedings of the International Conference of the IEEE Engineering in
Medicine and Biology (EMBC'04), pp. 2840--2843.

[55]

He, J. and Zelikovsky, A. (2004) `Linear Reduction for Haplotype Inference',
Proceedings of the Workshop on Algorithms in Bioinformatics (WABI'04), Vol.
3240, pp. 242--253.

[56]

Hudson, R. (1990) `Gene genealogies and the coalescent process', Oxford Survey of
Evolutionary Biology, Vol. 7, pp. 1--44.

[57]

Judson, R., Salisbury, B., Schneider, J., Windemuth, A. and Stephens, J.C. (2002)
`How many SNPs does a genome-wide haplotype map require?', Pharmacogenomics,
Vol. 3, pp. 379--391.

[58]

Patil, N., Berno, A., Hinds, D., Barrett, W., Doshi, J., Hacker, C., Kautzer, C., Lee,
D., Marjoribanks, C., McDonough, D., Nguyen, B., Norris, M., Sheehan, J., Shen, N.,
Stern, D., Stokowski, R., Thomas, D., Trulson, M., Vyas, K., Frazer, K., Fodor, S.
and Cox, D. (2001) `Blocks of limited haplotype diversity revealed by high-resolution
scanning of human chromosome', Science, Vol. 294, pp. 1719--1723.

[59]

Qin, Z., Niu, T., and Liu, J. (2002) `Partitioning-Ligation-ExpectationMaximization algorithm for haplotype inference with single-nucleotide

polymorphisms', American Journal of Human Genetics, Vol. 71, pp. 1242--1247.
[60]

Sebastiani, P., Lazarus, R., Weiss, S., Kunkel, L., Kohane, I., and Ramoni, M.

(2003) `Minimal haplotype tagging', Proceedings of the National Academy of
Sciences, Vol. 100, pp. 9900--9905.

121
[61]

Stram, D., Haiman, C., Hirschhorn, J., Altshuler, D., Kolonel, L., Henderson, B.
and Pike, M. (2003). `Choosing haplotype-tagging SNPs based on unphased genotype
data using as preliminary sample of unrelated subjects with an example from the
multiethnic cohort study', Human Heredity, Vol. 55, pp. 27--36.

[62]

Zhang, K., Qin, Z., Liu, J., Chen, T., Waterman, M., and Sun, F. (2004) `Haplotype
block partitioning and tag SNP selection using genotype data and their applications
to association studies', Genome Research, Vol. 14, pp. 908--916.

[63]

Zhang, K., Calabrese, P., Nordborg, M., Sun, F. (2002) `Haplotype Block Structure
and Its Applications in Association Studies: Power and Study Design', The American
Journal of Human Genetics, 71:1836-1894.

[64]

The International HapMap Project, http://www.hapmap.org

[65]

Daly, M., Rioux, J., Schaffner, S., Hudson, T. and Lander, E. (2001) `High Resolution
Haplotype Structure in the Human Genome', Nature Genetics, 29:229-232.

[66]

Gabriel, G., Schaffner, S., Nguyen, H., Moore, J., Roy, J., Blumenstiel, B., et al.
(2002) The Structure of Haplotype Blocks in the Human Genome, Science,
296:22252229.

[67]

Johnson, G.C.L., Esposito, L., Barratt, B.J., Smith, A.N., Heward, et al. (2001)
`Haplotype Tagging for the Identification of Common Disease Genes', Nature
Genetics, 29:233-237.

[68]

Clark AG. (2003) `Finding Genes Underlying Risk of Complex Disease by Linkage
Disequilibrium Mapping', Curr Opin Genet Dev., 13(3):296-302.

[69]

Zhao, H., Pfiffer, R. and Gail, MH. (2003) `Haplotype Analysis in Population

122
Genetics and Association Studies', Phamacogenomics, 4:171-178.
[70]

Goldestein, D. and Weale, M. (2001) `Population Genomics: Linkage Disequilibrium
Holds the Key', Current Biology, 11:576-579.

[71]

Kimmel, G. and Shamir, R. (2005) GERBIL: Genotype Resolution and Block
Identification Using Likelihood', Proceedings of the National Academy of Sciences
,102:158-162.

[72]

Stephens, M., Smith, N.J., and Donnelly, P. (2001) `A New Statistical Method for
Haplotype Reconstruction from Population Data', The American Journal of Human
Genetics, 68:97898.

[73]

Merikangas, KR., Risch, N. (2003) `Will the Genomics Revolution Revolutionize
Psychiatry', The American Journal of Psychiatry, 160:625-635.

[74]

Botstein, D., Risch, N. (2003) `Discovering Genotypes Underlying Human
Phenotypes: Past Successes for Mendelian Disease, Future Approaches for Complex
Disease', Nature Genetics, 33:228-237.

[75]

Ueda, H., Howson, J.M.M., Esposito, L. et al. (2003) `Association of the T Cell
Regulatory Gene CTLA4 with Susceptibility to Autoimmune Disease', Nature,
423:506-511.

[76]

Affymetrix (2005) http://www.affymetrix.com/products/arrays/.

[77]

Brinza, D. and Zelikovsky, A. (2006) 2SNP: Scalable Phasing Based on 2-SNP
Haplotypes. Bioinformatics, 22(3), 371--374.

[78]

Brinza, D. and Zelikovsky, A. (2006) Phasing of 2-SNP Genotypes based on Non-

123
Random Mating Model. International Workshop on Bioinformatics Research and
Applications (IWBRA'06), Proc. of ICCS 2006, LNCS 3992, 767-774.
[79]

Clark, A. (1990) Inference of haplotypes from PCR-amplified samples of diploid
populations. Mol Biol Evol., 7, 111--122.

[80]

Daly, M., Rioux, J., Schaffner, S., Hudson, T. and Lander, E. (2001) High resolution
haplotype structure in the human genome. Nat Genet., 29, 229--232.

[81]

Gabriel, G., Schaffner, S., Nguyen, H., Moore, J., Roy, J., Blumenstiel, B.,

Higgins, J., et al. (2002) The structure of haplotype blocks in the human genome.
Science, 296, 2225--2229.
[82]

Gusfield, D. (2003) Haplotype inference by pure parsimony. Proc. Symp. on
Comb. Pattern Matching, LNCS 2676, 144--155.

[83]

Halperin, E. and Eskin, E. (2004) Haplotype Reconstruction from Genotype Data
using Imperfect Phylogeny. Bioinformatics, 20, 1842--1849.

[84]

Hudson, R. (1990) Gene genealogies and the coalescent process. Oxford Survey of
Evolutionary Biology, 7, 1--44.

[85]

Hull, J., Rowlands, K., Lockhart, E., Sharland, M., Moore, C., Hanchard, N.,
Kwiatkowski, D.P. (2004) Haplotype mapping of the bronchiolitis susceptibility
locus near IL8. Am J Hum Genet., 114, 272-279

[86]

International HapMap Consortium. (2003) The International HapMap Project.
Nature, 426, 789--796, http://www.hapmap.org.

[87]

Kimmel, G. and Shamir, R. (2005) GERBIL: Genotype resolution and block

124
identification using likelihood. Proc Natl Acad Sci., 102, 158--162.
[88]

Kruglyak, L. and Nickerson, D. A. (2001) Variation is the spice of life. Nat Genet.,
27,234-236.

[89]

Lin, S., Chakravarti, A., and Cutler, D. (2004) Haplotype and missing data

inference in nuclear families. Genome Res, 14, 1624-1632.
[90]

Marchini, J., Cutler, D., Patterson, N., Stephens, M., Eskin, E., Halperin, E., Lin,
S., Qin, Z.S., Munro, H.M., Abecasis, G.R., Donnelly, P., and International HapMap
Consortium (2006) A Comparison of Phasing Algorithms for Trios and Unrelated
Individuals. Am. J. Human Genetics, 78,437--450.

[91]

Niu, T., Qin, Z., Xu, X. and Liu, J.S. (2002) Bayesian haplotype inference for
multiple linked single-nucleotide polymorphisms. Am J Hum Genet., 70, 157--169.

[92]

Niu T. (2004) Algorithms for inferring haplotypes. Genet Epidemiol.,27(4), 334--47.

[93]

Phasing Algorithm Benchmark Datasets,
http://www.stats.ox.ac.uk/marchini/phaseoff.html, July, 2006.

[94]

Schaffner, SF., Foo, C., Gabriel, S., Reich, D., Daly, MJ., Altshuler, D. (2005)
Calibrating a coalescent simulation of human genome sequence variation. Genome Res,
15, 1576-1583.

[95]

Stephens, M., Smith, N. and Donnelly, P. (2001) A new statistical method for
haplotype reconstruction from population data. Am J Hum Genet., 68, 978--989.

[96]

Stephens, M., and Donnelly, P. (2003) A Comparison of Bayesian Methods for
Haplotype Reconstruction from Population Genotype Data. Am. J. Human Genetics,

125
73,1162-1169.
[97]

Affymetrix (2005) http://www.affymetrix.com/products/arrays/.

[98]

Avi-Itzhak, H.I., Su, X. and de la Vega, F.M. (2003) Selection of minimum

subsets of single nucleotide polymorphism to capture haplotype block diversity, Proc.
of Pacific Symposium on Biocomputing, 8, 466--477.
[99]

Breiman, L. and Cutler, A. http://www.stat.berkeley.edu/users/breiman/RF

[100] Brinza, D., Perelygin, A., Brinton, M. and Zelikovsky, A. (2006) Search for
multi-SNP Disease Association, Proc. The Fifth Intl. Conf. on Bioinformatics of
Genome Regulation and Structure (BGRS'06), pp. 122-125.
[101] Brinza, D. and Zelikovsky, A. (2006) 2SNP: Scalable Phasing Based on 2-SNP
Haplotypes, Bioinformatics, 22(3), 371--373.
[102] Brinza, D. and Zelikovsky, A. (2006) Combinatorial Methods for Disease Association
Search and Susceptibility Prediction, Proc. 6th Workshop on Algorithms in
BioInformatics (WABI 2006), LNBI 4175, pp.286--297.
[103] Brinza, D., He, J. and Zelikovsky, A. (2006) Combinatorial Search Methods for
Multi-SNP Disease Association,Proc. of Intl. Conf. of the IEEE Engineering in
Medicine and Biology (EMBC'06), pp.5802-5805.
[104] Chapman, J.M., Cooper, J.D., Todd, J.A. and Clayton, D.G. (2003) Detecting
disease associations due to linkage disequilibrium using haplotype tags: a class of tests
and the determinants of statistical power, Human Heredity, 56, 18--31.
[105]

Clark AG. (2003) Finding Genes Underlying Risk of Complex Disease by Linkage

126
Disequilibrium Mapping, Curr Opin Genet Dev., 13(3), 296--302.
[106]

A.G.Clark et al (2005). Determinants of the success of whole-genome association testing,
Genome Res. 15, 1463--1467.

[107] Daly, M., Rioux, J., Schaffner, S., Hudson, T. and Lander, E. (2001) High
resolution haplotype structure in the human genome. Nature Genetics, 29, 229--232.
[108] International HapMap Consortium. (2003) The International HapMap Project.
Nature, 426, 789--796, http://www.hapmap.org.
[109] Joachims, T. http://svmlight.joachims.org/
[110]

Halldorsson, B.V., Bafna, V., Lippert, R., Schwartz, R., de la Vega, F.M., Clark, A.G.
and Istrail, S. (2004) Optimal haplotype block-free selection of tagging SNPs for
genome-wide association studies, Genome Research, 14, 1633--1640.

[111] Halperin, E., Kimmel, G. and Shamir, R. (2005) `Tag SNP Selection in Genotype
Data for Maximizing SNP Prediction Accuracy', Bioinformatics, 21, 195--203.
[112] He, J. and Zelikovsky, A. (2006) MLR-Tagging: Informative SNP Selection for
Unphased Genotypes Based on Multiple Linear Regression, Bioinformatics, epub.
[113] He, J. and Zelikovsky, A. (2006) Tag SNP Selection Based on Multivariate Linear
Regression, Proc. of Intl Conf on Computational Science (ICCS 2006), LNCS 3992,
750--757.
[114] Herbert, A., Gerry, N.P., McQueen, M.B. (2006) A Common Genetic Variant Is
Associated with Adult and Childhood Obesity, SCIENCE, 312, 279--284.
[115] Kimmel, G. and Shamir R. (2005) A Block-Free Hidden Markov Model for

127
Genotypes and Its Application to Disease Association, J. of Computational Biology
12(10), 1243--1260.
[116] Lee, P.H. and Shatkay, H (2006) BNTagger: Improved Tagging SNP Selection using
Bayesian Networks, Proc. of ISMB2006, in manuscript.
[117] Listgarten, J., Damaraju, S., Poulin B., Cook, L., Dufour, J., Driga, A., Mackey, J.,
Wishart, D., Greiner,R., and Zanke, B. (2004) Predictive Models for Breast Cancer
Susceptibility from Multiple Single Nucleotide Polymorphisms, Clinical Cancer
Research 10, 2725--2737.
[118] Mao, W., He, J., Brinza, D. and Zelikovsky, A. (2005) A Combinatorial Method for
Predicting Genetic Susceptibility to Complex Diseases, Proc. Intl. Conf. of the
IEEE Engineering In Medicine and Biology Society (EMBC'05), pp. 224--227.
[119] Mao, W., Brinza, D., Hundewale, N., Gremalschi, S. and Zelikovsky, A. (2006)
Genotype Susceptibility and Integrated Risk Factors for Complex Diseases, Proc. IEEE
Intl. Conf. on Granular Computing (GRC 2006), pp. 754--757.
[120] Marchini, J., Donnelley, P. and Cardon, L.R, (2005) Genome-wide strategies for
detecting multiple loci that influence complex diseases, Nature Genetics 37, 413--417.
[121] Nelson, M.R., Kardia, S.L., Ferrell, R.E., and Sing, C.F. (2001) A combinatorial
partitioning method to identify multilocus genotypic partitions that predict
quantitative trait variation, Genome Res. 11, 458--470.
[122] Spinola, M., Meyer, P., Kammerer, S. et al. (2006) Association of the PDCD5 Locus
With Lung Cancer Risk and Prognosis in Smokers, American Journal of Clinical
Oncology, 24:11.

128
[123] Stephens, M., Smith, N.J., and Donnelly, P. (2001) A New Statistical Method for
Haplotype Reconstruction from Population Data, The American Journal of Human
Genetics, 68, 978-998.
[124] Stram, D., Haiman, C., Hirschhorn, J., Altshuler, D., Kolonel, L., Henderson, B.
and Pike, M. (2003) Choosing haplotype-tagging SNPs based on unphased genotype
data using as preliminary sample of unrelated subjects with an example from the
multiethnic cohort study, Human Heredity, 55, 27--36.
[125] Tahri-Daizadeh, N., Tregouet, D. A., Nicaud, V., Manuel, N., Cambien, F., Tiret
L. (2003) Automated detection of informative combined effects in genetic
association studies of complex traits, Genome Res. 13, 1952--1960.
[126] Tomita, Y., Yokota, M. and Honda, H. (2005) Classification method for prediction of
multifactorial disease development using interaction between genetic and
environmental factors, IEEE CS Bioinformatics Conference, abstract.
[127] Ueda, H., Howson, J.M.M., Esposito, L. et al. (2003) Association of the T Cell
Regulatory Gene CTLA4 with Susceptibility to Autoimmune Disease, Nature,
423,506--511.
[128] Waddell, M., Page,D., Zhan, F., Barlogie, B., and Shaughnessy, J. (2005) Predicting
Cancer Susceptibility from SingleNucleotide Polymorphism Data: A Case Study in
Multiple Myeloma, Proc. of BIOKDD 2005.
[129] Zhang, K., Qin, Z., Liu, J., Chen, T., Waterman, M., and Sun, F. (2004)
Haplotype block partitioning and tag SNP selection using genotype data and their
applications to association studies, Genome Research, 14, 908--916.

129
[130] Zhang P., Sheng H. and Uehara R. (2004) A double classification tree search
algorithm for index SNP selection, BMC Bioinformatics, 5, 89--95.
[131] Affymetrix (2005) http://www.affymetrix.com/products/arrays/.
[132] Brinza, D. and Zelikovsky, A. (2006) Combinatorial Methods for Disease Association
Search and Susceptibility Prediction, Proc. 6th Workshop on Algorithms in
BioInformatics (WABI 2006), LNBI, 4175, 286--297
[133] Brinza, D., He, J. and Zelikovsky, A. (2006) Combinatorial Search Methods for
Multi-SNP Disease Association, Proc. Intl. Conf. of the IEEE Engineering In
Medicine and Biology Society (EMBC'06), pp. 5802--5805.
[134] Brinza, D., Perelygin, A., Brinton, M. and Zelikovsky, A. (2006) Search for
multi-SNP Disease Association, Proc. Fifth Intl. Conf. on Bioinformatics of

Genome Regulation and Structure (BGRS'06), pp. 122--125.
[135] Brinza, D. and Zelikovsky, A. (2006) Combinatorial Analysis of Disease Association
and Susceptibility for Rheumatoid Arthritis SNP Data, Proc. of 15-th Genetic
Analysis Workshop (GAW15), 13, 6--11.
[136] Clark AG. (2003) Finding Genes Underlying Risk of Complex Disease by Linkage
Disequilibrium Mapping, Curr Opin Genet Dev., 13(3), 296--302.
[137]

A.G.Clark et al (2005). Determinants of the success of whole-genome association testing,
Genome Res, 15, 1463--1467.

[138] Daly, M., Rioux, J., Schaffner, S., Hudson, T. and Lander, E. (2001) High
resolution haplotype structure in the human genome. Nature Genetics, 29, 229--232.

130
[139] International HapMap Consortium. (2003) The International HapMap Project.
Nature, 426, 789--796, http://www.hapmap.org.
[140] Herbert, A., Gerry, N.P., McQueen, M.B. (2006) A Common Genetic Variant Is
Associated with Adult and Childhood Obesity, SCIENCE, 312, 279--284.
[141] Kimmel, G. and Shamir R. (2005) A Block-Free Hidden Markov Model for
Genotypes and Its Application to Disease Association. J. of Computational Biology,
Vol. 12, No. 10: 1243--1260.
[142] Mao, W., Brinza, D., Hundewale, N., Gremalschi, S. and Zelikovsky, A. (2006)
Genotype Susceptibility and Integrated Risk Factors for Complex Diseases, Proc. IEEE
Intl. Conf. on Granular Computing (GRC 2006), pp. 754--757.
[143] Marchini, J., Donnelley , P. and Cardon, L.R, (2005) Genome-wide strategies for
detecting multiple loci that influence complex diseases, Nature Genetics, 37, 413-417.
[144] Spinola, M., Meyer, P., Kammerer, S. et al. (2006) Association of the PDCD5 Locus
With Lung Cancer Risk and Prognosis in Smokers, American Journal of Clinical
Oncology, 24:11.
[145] Ueda, H., Howson, J.M.M., Esposito, L. et al. (2003) Association of the T Cell
Regulatory Gene CTLA4 with Susceptibility to Autoimmune Disease, Nature,
423,506--511.
[146] Anderson, M. (2001) `Crohn's: An Autoimmune or Bacteria-Related Disease?', The
Scientist, 22:15-16.
[147] Botstein, D., Risch, N. (2003) `Discovering Genotypes Underlying Human Phe-

131
notypes: Past Successes for Mendelian Disease, Future Approaches for Complex
Disease', Nature Genetics, 33:228-237.
[148] Breiman, L. and Cutler, A.
http://www.stat.berkeley.edu/users/breiman/RandomForests/
[149] Brinza, D. and Zelikovsky, A. (2006) 2SNP: Scalable Phasing Based on 2-SNP
Haplotypes, Bioinformatics, 22(3):371-3.
[150] Joachims, T. http://svmlight.joachims.org/
[151] Clark AG. (2003) `Finding Genes Underlying Risk of Complex Disease by Linkage
Disequilibrium Mapping', Curr Opin Genet Dev., 13(3):296-302.
[152] Clinical Epidemiology Glossary, http://www.med. ualberta.ca/ebm/define.htm.
[153]

Daly, M., Rioux, J., Schaffner, S., Hudson, T. and Lander, E. (2001) `High Resolution
Haplotype Structure in the Human Genome', Nature Genetics, 29:229-232.

[154] Gabriel, G., Schaffner, S., Nguyen, H., Moore, J., Roy, J., Blumenstiel, B., et al.
(2002) `The Structure of Haplotype Blocks in the Human Genome', Science,
296:2225-2229.

[155] GLPK (2000). GNU Linear Programming Kit. http://www.gnu.org.
[156]

The International HapMap Project, http://www.hap map.org

[157] Johnson, G.C.L., Esposito, L., Barratt, B.J., Smith, A.N., Heward, et al. (2001)
`Haplotype Tagging for the Identification of Common Disease Genes', Nature
Genetics, 29:233-237.

[158] Kimmel, G. and Shamir R.. (2005) A Block-Free Hidden Markov Model for

132
Genotypes and Its Application to Disease Association. J. of Computational Biology,
Vol. 12, No. 10: 1243-1260.
[159] Listgarten, J., Damaraju, S., Poulin B., Cook, L., Dufour, J., Driga, A.,
Mackey, J., Wishart, D., Greiner,R., and Zanke, B.. (2004) Predictive Models for
Breast Cancer Susceptibility from Multiple Single Nucleotide Polymorphisms.
mphClinical Cancer Research, Vol. 10, 2725-2737, 2004.
[160] Mao, W., He, J., Brinza D. and Zelikovsky, A. (2005) `A Combinatorial Method for
Predicting Genetic Susceptibility to Complex Diseases', Proc. International Conf. of
the IEEE Engineering in Medicine and Biology (EMBC'05), pp.224-227.
[161] Merikangas, KR., Risch, N. (2003) `Will the Genomics Revolution Revolutionize
Psychiatry', The American Journal of Psychiatry, 160:625-635.
[162]

Tomita, Y., Yokota, M. and Honda, H. (2005) Classification method for prediction of
multifactorial disease development using interaction between genetic and
environmental factors, IEEE computational systems bioinformatics conference,
abstract.

[163] Ueda, H., Howson, J.M.M., Esposito, L. et al. (2003) `Association of the T Cell
Regulatory Gene CTLA4 with Susceptibility to Autoimmune Disease', Nature,
423:506-511.

[164] Waddell, M., Page,D., Zhan, F., Barlogie, B., and Shaughnessy, J..(2004) Predicting
Cancer Susceptibility from SingleNucleotide Polymorphism Data: A Case Study in
Multiple Myeloma. Proceddings of BIOKDD 2005, 05, 2005.
[165] Zhang, K., Calabrese, P., Nordborg, M., Sun, F. (2002) `Haplotype Block Structure

133
and Its Applications in Association Studies: Power and Study Design', The American
Journal of Human Genetics, 71:1836-1894.
[166] Carr, R.D., Doddi, S., Konjevod, G., and Marathe, M., (2000) On the red-blue set
cover problem, Proc. of 11-th annual ACM-SIAM symposium on Discrete
algorithms , pp. 345--353.

